SEARCH
検索詳細
原田 一顕 (ハラダ カズアキ)
| 北海道大学病院 | 助教 |
研究者基本情報
■ 学位■ URL
researchmap URLホームページURL■ ID 各種
研究者番号
- 30878450
研究活動情報
■ 論文- Study protocol of the C-SOLVE (JACCRO GC-12) trial; a randomized, non-comparative phase II trial of CapeOX or SOX plus zolbetuximab in HER2-negative, CLDN18.2-positive unresectable advanced gastric or esophagogastric junction cancer.
Satoshi Yuki; Hisato Kawakami; Kazuaki Harada; Yohei Kubota; Kyongsun Pak; Yoshihiro Kakeji; Masanori Terashima; Eishi Baba; Kei Muro; Yu Sunakawa; Wataru Ichikawa; Masashi Fujii
BMC cancer, 2026年07月17日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Capecitabine + oxaliplatin (CapeOX) + zolbetuximab and 5-FU + oxaliplatin (mFOLFOX6) + zolbetuximab are recommended as first-line treatments for chemotherapy-naïve patients with HER2-negative, CLDN18.2-positive advanced gastric or esophagogastric junction cancer. However, no prospective trials have evaluated the efficacy and safety of S-1 + oxaliplatin (SOX) + zolbetuximab. This study is planned as a non-comparative, prospective, randomized phase II clinical trial to evaluate the efficacy and safety of SOX + zolbetuximab in chemotherapy-naïve patients with HER2-negative, CLDN18.2-positive advanced gastric or esophagogastric junction cancer. METHODS/DESIGN: This randomized study will enroll patients ≥ 18 years old with histologically confirmed HER2-negative, CLDN18.2-positive (IHC defined as ≥ 75% of tumour cells showing moderate-to-strong membranous CLDN18 staining) advanced gastric or esophagogastric junction cancer. Participants (n = 140) will be randomly assigned (1:1) to receive either SOX + zolbetuximab or CapeOX + zolbetuximab. The primary endpoint is the 12-month progression-free survival (PFS) rate, with a threshold of 17% and an expected rate of 33% for SOX + zolbetuximab. To account for a 10% deviation risk, the target enrollment for each arm is 70 patients. CapeOX + zolbetuximab will serve as a prospective observational arm without hypothesis testing. Secondary endpoints will include PFS, overall survival, objective response rate, disease control rate, duration of response, time to response, and safety. The enrollment period is 2 years, followed by a 2-year observation period. DISCUSSION: Since replacing capecitabine with S-1 should provide the same level of therapeutic efficacy, SOX + zolbetuximab may be increasingly used to treat advanced gastric or esophagogastric junction cancer in Asian countries. Verifying the efficacy and safety of SOX + zolbetuximab is thus an important task. TRIAL REGISTRATION: The protocol has been registered at the website of the Japan Registry of Clinical Trials (JRCT), Japan (protocol ID jRCTs031240510, protocol version: 1.11) on November 26, 2024. The details are available at https://jrct.mhlw.go.jp/. - Randomized phase III trial of gemcitabine plus nab-paclitaxel versus gemcitabine plus S-1 as neoadjuvant chemotherapy for resectable pancreatic cancer in geriatric patients: JCOG2101C (PRESTIGE study).
Yusuke Sano; Masato Ozaka; Shuichi Aoki; Shogo Nomura; Noriko Mitome; Haruhiko Fukuda; Takahiro Mizui; Keiko Kamei; Masaaki Murakawa; Hidetoshi Eguchi; Manabu Kawai; Hirofumi Shirakawa; Shintaro Yagi; Nobumasa Mizuno; Amane Takahashi; Hidenori Takahashi; Naoki Ikenaga; Naohiro Okano; Shigeru Marubashi; Yuichi Nagakawa; Shinjiro Kobayashi; Taro Okazaki; Kazuaki Harada; Hirofumi Akita; Toru Otsuru; Shingo Kagawa; Seiko Hirono; Satoru Seo; Shiho Arima; Naoto Gotohda; Tsutomu Fujii; Etsuro Hatano; Michiaki Unno; Makoto Ueno
Japanese journal of clinical oncology, 56, 7, 904, 909, 2026年07月06日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Neoadjuvant gemcitabine plus S-1 (GS) followed by surgery and adjuvant S-1 is the standard of care for resectable pancreatic cancer. Since ~73% of newly diagnosed pancreatic cancer patients are aged ≥70, effective treatments are strongly needed in this geriatric population. In unresectable pancreatic cancer, gemcitabine plus nab-paclitaxel (GnP) is widely used, even among geriatric patients. To evaluate the survival advantage of neoadjuvant GnP over GS for geriatric patients with resectable pancreatic cancer, an open-label randomized phase III trial (JCOG2101C) has been initiated since October 2022. A total of 400 patients will be enrolled from 28 institutions within 3 years. The primary endpoint is overall survival. This trial was registered at the Japan Registry of Clinical Trials as jRCTs031220351 [https://jrct.mhlw.go.jp/latest-detail/jRCTs031220351]. - A phase II trial of ramucirumab and docetaxel as second-line treatment for patients with advanced gastric cancer (HGCSG 1903).
Yasuyuki Kawamoto; Kentaro Sawada; Kazuaki Harada; Iori Motoo; Takayuki Ando; Susumu Sogabe; Yoshimitsu Kobayashi; Masayoshi Dazai; Michio Nakamura; Kazuteru Hatanaka; Atsushi Ishiguro; Atsushi Sato; Shintaro Nakano; Yoshiaki Shindo; Ayumu Hosokawa; Ken Ito; Ayumu Yoshikawa; Akira Ueda; Kayoko Iuchi; Isao Yokota; Satoshi Yuki; Yoshito Komatsu
Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association, 29, 4, 808, 815, 2026年07月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Ramucirumab has shown efficacy in combination with paclitaxel in the second-line treatment of advanced gastric cancer (AGC). The efficacy and safety regarding the combination therapy of ramucirumab and docetaxel have not been reported. This treatment could reduce the incidence of neuropathy and patients' hospital visits. METHODS: This was a multicenter, single-arm phase II trial. Patients with AGC who were refractory or intolerant to primary treatment were eligible. Patients received ramucirumab at a dose of 8 mg/kg on day1 and 15, and docetaxel at a dose of 60 mg/m2 on day1 of a 28-day cycle. The primary endpoint was overall response rate (ORR). The secondary endpoints were progression-free survival (PFS), overall survival (OS), relative dose intensity, and safety. RESULTS: A final analysis of efficacy and safety was performed in 35 patients. ORR was 25.7% (90% confidence interval [CI] 14.1-40.6) and disease control rate was 74.3% (90%CI 59.4-85.9). Median PFS and OS were 3.1 months (95%CI 2.1-4.2) and 11.5 months (95%CI 9.2-13.9), respectively. Grade 3 or higher adverse events that occurred in more than 10% of patients were neutropenia, leucopenia, febrile neutropenia, hypertension, and anorexia. The study protocol was amended to allow primary granulocyte-colony stimulating factor (G-CSF) prophylaxis during study period. There was no one incident febrile neutropenia after the protocol amendment. Peripheral sensory neuropathy occurred in 65.7% of all grades, with no incidence of grade 3 or higher. CONCLUSIONS: The combination therapy of ramucirumab and docetaxel demonstrated some efficacy for AGC. Caution is required regarding the occurrence of febrile neutropenia. This treatment might be considered as an option for second-line treatment of patients with AGC. - Phase II basket study of brigatinib for ALK fusion-positive solid tumors: WJOG15221M/ALLBREAK (a decentralized clinical trial design).
Tomoki Sakakida; Toshiki Masuishi; Takuma Onoe; Keigo Komine; Kan Yonemori; Takao Fujisawa; Kazuaki Harada; Satoshi Hamauchi; Kentaro Tokumo; Taito Esaki; Yukihiko Hiroshima; Satomi Watanabe; Masako Asayama; Waki Hosoda; Hiroya Taniguchi; Hidetoshi Hayashi; Kei Muro
Future oncology (London, England), 22, 11, 1273, 1279, 2026年05月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Anaplastic lymphoma kinase (ALK) rearrangements, oncogenic drivers found in 3-5% of non-small cell lung cancer (NSCLC), are also detected in 0.2% of other solid tumors with poor prognosis. Brigatinib, a second-generation ALK-tyrosine kinase inhibitor (ALK-TKI), has shown potential efficacy in ALK fusion-positive tumors besides NSCLC, supported by preclinical studies and case reports. The WJOG15221M/ALLBREAK trial was designed to evaluate the safety and efficacy of brigatinib in these rare cancers.This multicenter, open-label, single-arm, phase II basket trial enrolls patients with advanced or recurrent ALK fusion-positive solid tumors who are refractory to or intolerant of standard therapies. By adopting a decentralized clinical trial (DCT) platform, the study allows patients to participate either through on-site visits or video conferencing systems at their nearby hospitals, thereby enhancing accessibility and inclusivity, while facilitating enrollment from diverse locations. ALK fusion genes are identified by next-generation sequencing (NGS) or by immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH). Due to rapid enrollment, the target sample size was expanded to 28 patients. The primary endpoint is objective response rate confirmed by central assessment; secondary endpoints include duration of response, progression-free survival, overall survival, and safety.Clinical trial registration: jRCT2041210148 (https://jrct.mhlw.go.jp). - High CD73 Expression Is Associated with Poor Prognosis in Biliary Tract Cancer Through Reduced Stromal Tumor-Infiltrating Lymphocytes
Shoya Shiratori; Kazumichi Kawakubo; Kanako C. Hatanaka; Takuma Kobayashi; Teppei Konishi; Yoshiki Shinomiya; Soichiro Oda; Shunichiro Nozawa; Hiroki Yonemura; Ryo Sugiura; Kazuaki Harada; Yoshitsugu Nakanishi; Takehiro Noji; Shinya Tanaka; Satoshi Hirano; Masaki Kuwatani; Yutaka Hatanaka; Naoya Sakamoto
Cancers, 18, 6, 975, 975, MDPI AG, 2026年03月18日, [査読有り]
研究論文(学術雑誌), Background: Biliary tract cancer (BTC) is an aggressive malignancy with limited therapeutic options and a poor prognosis. CD73 is upregulated under hypoxic conditions and promotes tumor progression. However, its clinical role in BTC and interaction with tumor-infiltrating lymphocytes (TILs) remain unclear. This study aimed to elucidate the association between CD73 expression and prognosis in BTC, as well as its impact on the tumor microenvironment (TME) and TILs. Methods: This retrospective study included 100 patients who underwent curative BTC surgery at Hokkaido University Hospital between 2018 and 2023. Formalin-fixed tumor specimens were analyzed using DeepPathFinder™ (biomy Inc., Tokyo, Japan), an AI-based digital pathology platform enabling objective quantification of CD73 expression and lymphocyte infiltration within tumoral (T) and stromal (S) compartments. Immunohistochemistry for CD3, CD8, Foxp3, and CD163 was used to identify T-cell subsets and macrophages. Associations between CD73, TIL subsets, and overall survival (OS) were assessed using the Kaplan–Meier, Cox regression, and Spearman correlation analyses. Results: High T-CD73 expression was associated with shorter OS (hazard ratio [HR] = 1.97, p = 0.041), whereas S-CD73 showed no prognostic relevance. Conversely, high S-TIL density was correlated with improved survival (HR = 0.49, p = 0.032). T-CD73 expression was negatively correlated with stromal CD3+ and CD8+ T-cell densities, indicating selective suppression of stromal cytotoxic T-lymphocyte (CTL) infiltration. No significant correlations were observed between Foxp3+ T cells and CD163+ M2 macrophages. Conclusions: CD73 upregulation in tumor cells impairs stromal CTL and TIL activity, leading to a poor prognosis. Spatial distribution, rather than total TIL number, better reflects effective anti-tumor immunity. - Predictors of the early discontinuation of anamorelin hydrochloride in gastrointestinal cancer-related cachexia: a multicenter retrospective cohort study (HGCSG2201).
Kazuaki Harada; Shinya Kajiura; Kentaro Sawada; Kazuteru Hatanaka; Atsushi Sato; Ken Ito; Hotaka Tamura; Ayako Doi; Takayuki Ando; Michio Nakamura; Hiroshi Nakatsumi; Tetsuhito Muranaka; Susumu Sogabe; Takahiro Ishii; Shintaro Nakano; Masayoshi Dazai; Yusuke Sasaki; Yasuyuki Kawamoto; Satoshi Yuki; Yuh Sakata; Yoshito Komatsu
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 34, 3, 221, 221, 2026年02月19日, [査読有り], [筆頭著者, 責任著者], [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Anamorelin hydrochloride (ANAM), used to treat cancer cachexia, is often discontinued early in clinical practice. Herein, we explored the clinical factors associated with the early discontinuation (Ed) of ANAM and examined its effect on treatment outcomes. METHODS: Clinical data of patients with gastrointestinal cancers who were administered ANAM between April and November 2021 from 16 institutions were retrospectively collected. Ed was defined as ANAM discontinuation within 4 weeks of initiation. ANAM efficacy was compared between the continuation (Co) and Ed groups. RESULTS: Of the 123 patients, 50 had an Ed of ANAM. The most common reasons were cancer progression (36%), adverse events (30%), and insufficient efficacy (22%). Age ≥ 75 years (odds ratio [OR] 4.11, 95% confidence interval [CI] 1.418-11.952, p = 0.009), no concomitant anticancer chemotherapy (OR 8.84, 95% CI 1.900-41.151, p = 0.006), and modified Glasgow prognostic score 2 (OR 2.65, 95% CI 1.065-6.604, p = 0.036) were significant risk factors for Ed. At 3 ± 1 weeks after ANAM initiation, the number of patients with increased appetite (Co 50.8% vs Ed 14.3%, p = 0.012) and food intake (Co 59.2% vs Ed 20.0%, p = 0.002) were significantly higher in the Co group than in the Ed group. CONCLUSION: Initiating ANAM while patients can still receive concurrent chemotherapy may help prevent Ed and achieve better therapeutic benefit. Trial registration The registration number in the UMIN Clinical Trial Registry is UMIN000051550. The date of registration is July 7, 2023. - Safety and efficacy of conversion therapy for metastatic esophageal cancer: exploratory analysis of JCOG1314.
Satoru Matsuda; Takahiro Tsushima; Hirofumi Kawakubo; Shuichi Hironaka; Yasuhiro Tsubosa; Katsuyuki Sakanaka; Junya Oguma; Shigenori Kadowaki; Shigeru Tsunoda; Hiroki Hara; Kazuo Koyanagi; Toshifumi Yamaguchi; Kazuaki Harada; Masanobu Takahashi; Keiko Minashi; Eishi Baba; Keita Sasaki; Ryunosuke Machida; Hiroya Takeuchi
Esophagus : official journal of the Japan Esophageal Society, 23, 1, 111, 119, 2026年01月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Recent advances in multimodal treatments indicate that conversion therapy (CT) is a viable option for metastatic esophageal cancer (EC). JCOG1314 was a randomized phase III trial to confirm the survival benefit of docetaxel plus cisplatin plus 5-fluorouracil (DCF) versus cisplatin plus 5-fluorouracil (CF) for metastatic EC. The purpose of this analysis was to evaluate the safety and survival of CT in patients enrolled in JCOG1314. METHODS: CT was defined as surgery or chemoradiotherapy (CRT) aimed at cure following initial treatment for tumors that were initially unresectable because of distant metastasis. Clinicopathological factors, surgical outcomes, toxicities during CRT, and survival were compared between the CT and non-CT groups. RESULTS: Of 240 patients enrolled in JCOG1314, excluding patients with recurrent disease, 154 with initially unresectable EC because of distant metastasis were selected. Of these patients, 21 received CT, which included conversion surgery (n = 5) and conversion CRT (n = 16). There was no significant difference in the number of metastatic organs or chemotherapy regimen between the CT and non-CT groups. The most common M1 factor in the CT group was the thoracic lymph node. The 3-year overall survival (OS) for the CT and non-CT groups was 52.4 and 14.3%, respectively. Multivariable analysis revealed that CT patients showed significantly better OS compared with the non-CT group (HR 0.36, 95% CI 0.19-0.67, p < 0.01). CONCLUSION: CT may be safely performed with a favorable prognosis in EC. A prospective study is warranted to determine whether CT improves survival in metastatic EC. - Successful re-administration after nano-liposomal irinotecan-induced severe hypersensitivity reaction: a case report.
Ryota Kanno; Yoshitaka Saito; Yoh Takekuma; Kazuaki Harada; Yoshito Komatsu; Mitsuru Sugawara
Journal of pharmaceutical health care and sciences, 11, 1, 110, 110, 2025年12月22日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Nano-liposomal irinotecan (nal-IRI) combined with 5-fluorouracil (5-FU) and levofolinate has been reported to extend the survival of patients with pancreatic cancer and represents an effective second-line treatment. Nal-IRI encapsulates IRI in liposomes modified with polyethylene glycol (PEGylation), which can lead to infusion reactions. Hypersensitivity reactions (HSR) to chemotherapeutic agents include both allergic and infusion reactions, which are difficult to distinguish. Severe HSR can be fatal; however, discontinuation of the suspected drug directly affects the treatment strategy. We report a case of severe HSR during the first nal-IRI administration, in which treatment was successfully continued with supportive management. CASE PRESENTATION: A woman in her early 80s with metastatic pancreatic cancer received nal-IRI + 5-FU + levofolinate as second-line treatment. Five minutes after the initiation of the first nal-IRI infusion, the patient developed a tightening sensation in the head, respiratory distress, convulsions, and loss of consciousness, with percutaneous oxygen saturation dropping to the 80% range. The nal-IRI infusion was immediately discontinued, and emergency management was initiated with intravenous infusion of hydrocortisone, famotidine, d-chlorpheniramine maleate, and oxygen administration, resulting in symptom improvement. Given the limited treatment options for metastatic pancreatic cancer and the patient's strong desire to continue therapy, we decided to re-administer the regimen with intensified management, increasing dexamethasone to 19.8 mg and adding famotidine 20 mg and d-chlorpheniramine maleate 5 mg. Furthermore, we adopted a three-step dose-escalation method. The infusion was started at one-third of the standard rate, increased to two-thirds after 30 min, and finally adjusted to the full rate after another 30 min, after confirming the absence of HSR symptoms. Consequently, the patient did not exhibit any signs of HSR, and the same administration method was continued for 11 cycles until disease progression. CONCLUSIONS: The novelty of this report lies in presenting, for the first time, the detailed course and process by which treatment was successfully continued in a patient experiencing severe HSR upon initial nal-IRI administration, through enhanced supportive care tailored to the characteristics of the drug and stepwise dose adjustment. - Urinary Titin as a Non-Invasive Biomarker for Sarcopenia Sex Differences in Unresectable Digestive Malignancies: A Retrospective Cohort Study.
Shiho Kaneko; Kazuaki Harada; Masatsugu Ohara; Shintaro Sawaguchi; Tatsuya Yokoyama; Koichi Ishida; Yasuyuki Kawamoto; Satoshi Yuki; Yoshito Komatsu; Naoya Sakamoto
International journal of molecular sciences, 26, 14, 2025年07月15日, [査読有り], [責任著者], [国際誌]
英語, 研究論文(学術雑誌), The prognosis of sarcopenia is poor in cancer patients. Recently, urinary titin, a biomarker of muscle damage, has been suggested as a potential marker for sarcopenia. However, its utility in patients with unresectable digestive malignancies remains unclear. In addition, sex differences have been reported in the association between sarcopenia and urinary titin levels. This study aimed to evaluate urinary titin as a diagnostic marker for unresectable digestive malignancies, focusing on sex differences. This retrospective study enrolled 96 patients (58 males, 38 females; median age 70), and urinary titin was evaluated as a diagnostic biomarker in relation to clinical factors (e.g., age, Eastern Cooperative Oncology Group performance status [ECOG PS], albumin [Alb]) and muscle indicators (e.g., psoas muscle index [PMI], handgrip strength). In male patients, urinary titin levels were significantly higher in the sarcopenia subgroup (5.78 vs. 2.79 pmol/mgCr, p = 0.008), and multivariate analyses identified urinary titin as an independent predictor of sarcopenia (odds ratio 13.4, p = 0.028). The receiver operating characteristic (ROC) analysis demonstrated fair diagnostic performance (area under the curve [AUC] 0.729), with an optimal cutoff value of 3.676 pmol/mgCr. Urinary titin may serve as a useful non-invasive diagnostic biomarker for sarcopenia in patients with unresectable digestive malignancies, particularly in males. These findings suggest that sex-specific approaches are required for sarcopenia assessment with urinary titin. - Lack of association between SLFN11 expression and treatment efficacy or survival outcomes in patients with pancreatic ductal adenocarcinoma
Takeaki Nakamura; Kanako C. Hatanaka; Yasuyuki Kawamoto; Shiho Kaneko; Koichi Ishida; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Yutaka Hatanaka; Naoya Sakamoto
Journal of Cancer Research and Clinical Oncology, 151, 5, Springer Science and Business Media LLC, 2025年05月10日, [査読有り]
研究論文(学術雑誌) - Subcutaneous adipose tissue radiodensity as a predictor of poor prognosis in advanced biliary tract cancer
Ryo Sugiura; Yasuyuki Kawamoto; Masaki Kuwatani; Kazumichi Kawakubo; Kazuaki Harada; Masatsugu Ohara; Hiroki Yonemura; Shunichiro Nozawa; Naoya Sakamoto
Journal of Hepato-Biliary-Pancreatic Sciences, Wiley, 2025年01月08日, [査読有り]
研究論文(学術雑誌), Abstract
Background
High subcutaneous adipose tissue radiodensity (SATr), an indirect surrogate marker of adipose tissue quality, was associated with poor prognosis in various cancers. The present study aimed to assess the association of SATr with survival outcomes in patients with advanced biliary tract cancer (BTC).
Methods
This retrospective, single‐center study included patients with unresectable or recurrent BTC who underwent chemotherapy/chemoradiotherapy. Overall survival (OS) and progression‐free survival (PFS) were assessed using the log‐rank test and the Cox proportional hazards model according to the SATr status.
Results
The study cohort included 234 patients, including 38 and 196 patients with high and non‐high SATr, respectively. The median OS durations were 10.5 and 17.4 months (HR = 1.72, 95% CI: 1.19–2.49, p < .01) and the median PFS durations were 4.9 and 8.0 months (HR = 1.52, 95% CI: 1.05–2.20, p = .03) in patients with high and non‐high SATr, respectively. By multivariate analysis, high SATr, neutrophil/lymphocyte ratio >5, modified Glasgow prognostic score 1–2, and serum carcinoembryonic antigen >5.0 ng/mL were predictors for OS (HR, 1.66, 2.42, 2.00, and 1.56, respectively; p < .05). By multivariate analysis, metastatic disease status, high SATr, neutrophil/lymphocyte ratio >5, and modified Glasgow prognostic score 1–2 were independent risk factors for worse PFS (HR, 1.56, 1.56, 1.81, and 1.57, respectively; p < .05).
Conclusions
High SATr was associated with risk of tumor progression and poor prognosis in patients with advanced BTC treated by palliative chemotherapy/chemoradiotherapy. - Ultrasound-detected gastric changes related to zolbetuximab-induced emesis: a case series.
Kazuaki Harada; Koichi Ishida; Shiho Kaneko; Tatsuya Yokoyama; Shintaro Sawaguchi; Takeaki Nakamura; Yasuyuki Kawamoto; Satoshi Yuki; Mutsumi Nishida; Naoya Sakamoto; Yoshito Komatsu
Frontiers in oncology, 15, 1686245, 1686245, 2025年, [査読有り], [筆頭著者], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Zolbetuximab prolongs survival in patients with claudin18.2 (CLDN18.2)-positive gastric cancer (GC) and gastroesophageal junction cancer. However, it is associated with an increased risk of emesis, and its underlying mechanism remains unclear. CASE PRESENTATION: This report presents three cases of advanced GC that underwent abdominal ultrasonography (US) during zolbetuximab administration. In two patients with primary gastric lesions, severe nausea occurred during the first treatment cycle. US findings revealed increased echogenicity of the submucosal layer, enhanced layer stratification, and increased blood flow signals, which improved as the emesis subsided. During the second cycle, emesis was milder, and US findings revealed only slight changes. In the third patient who underwent total gastrectomy, no nausea or abnormal US findings were observed. CONCLUSION: These US findings indicate gastric tumor tissue injury due to zolbetuximab, which is associated with emesis. US is a valuable tool for further elucidating the mechanisms underlying zolbetuximab-induced emesis and may also contribute to the prediction and prevention of this adverse event. STATEMENT: Zolbetuximab treatment has been reported to improve survival in patients with HER2-negative, CLDN18.2-positive advanced, unresectable, or recurrent gastric and gastroesophageal junction cancers. However, it is associated with a high incidence of nausea, particularly during the first infusion, and the underlying mechanism remains unclear. We present three cases of advanced or recurrent gastric cancer treated with zolbetuximab, during which abdominal ultrasonography (US) was performed. In two cases with primary gastric tumors, US revealed characteristic changes in the gastric wall at the onset of nausea, suggestive of edema and inflammation. These changes appeared prior to the symptoms and resolved as nausea improved. Nausea during the second infusion was milder, with less pronounced US changes. The third case includes a patient who had undergone total gastrectomy; the patient did not experience nausea, and no gastrointestinal changes were observed on US. This is the first report to describe US findings associated with zolbetuximab-induced nausea. These observations suggest that gastric wall changes detectable using US are closely linked to nausea and may reflect underlying gastric injury. This report also highlights the potential of bedside US monitoring to help predict and prevent nausea during zolbetuximab therapy. - Perioperative chemotherapy with nivolumab for HER2-negative locally advanced gastric cancer: a case series.
Yuta Toji; Shintaro Takeuchi; Yuma Ebihara; Yo Kurashima; Kazuaki Harada; Mariko Hayashi; Hirotake Abe; Hideyuki Wada; Satoko Yorinaga; Toshiaki Shichinohe; Utano Tomaru; Yoshito Komatsu; Satoshi Hirano
Surgical case reports, 10, 1, 200, 200, 2024年08月28日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Nivolumab with chemotherapy has been transformative for metastatic gastric cancer (GC). The potential of this regimen for local tumor control could be utilized for perioperative chemotherapy in locally advanced GC with bulky tumors or lymph node metastasis involving other organs. CASE PRESENTATION: Five patients with HER2-negative advanced GC were treated with nivolumab and oxaliplatin-based chemotherapy. All patients presented with clinical stage III or IVA GC with tumors in contact with either the pancreas or liver. Following chemotherapy, all tumors demonstrated shrinkage, allowing successful radical gastrectomies including four minimally invasive approach without postoperative complications. Four patients avoided combined resection of other organs. CONCLUSIONS: Perioperative chemotherapy with nivolumab was effective for local disease control in this case series. This regimen could be a promising treatment approach for locally advanced GC; however, its survival benefits should be evaluated in clinical trials. - A multicenter, prospective, phase II trial of second-line aflibercept plus FOLFIRI in patients with metastatic colorectal cancer refractory to an anti-EGFR antibody: HGCSG1801.
Hiroshi Nakatsumi; Yoshito Komatsu; Kazuaki Harada; Yasuyuki Kawamoto; Satoshi Yuki; Kentaro Sawada; Atsushi Ishiguro; Susumu Sogabe; Takayuki Ando; Yusuke Sasaki; Ayumu Yoshikawa; Michio Nakamura; Masayoshi Dazai; Miki Tateyama; Osamu Muto; Masahito Kotaka; Tamotsu Sagawa; Tetsuhito Muranaka; Kazuteru Hatanaka; Ryo Takagi; Yu Sakata
International journal of cancer, 2024年08月14日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), Aflibercept (AFL) plus FOLFIRI prolongs overall survival (OS) in patients with metastatic colorectal cancer (mCRC). However, there is limited evidence on the efficacy and safety of AFL plus FOLFIRI previously treated with anti-epidermal growth factor receptor (EGFR) agents. Therefore, we conducted a prospective open-label phase II trial evaluating the efficacy and safety of AFL plus FOLFIRI in Japanese patients with mCRC failing a prior oxaliplatin-based chemotherapy plus an anti-EGFR agent. AFL (4 mg/kg iv) followed by FOLFIRI (irinotecan 180 mg/m2, leucovorin 200 mg/m2 iv, bolus 5-fluorouracil [5-FU] 400 mg/m2, and infusional 5-FU 2400 mg/m2/46 h) was given every 2 weeks until progression or unacceptable toxicities. The primary endpoint was progression-free survival (PFS) rate at 6 months. Forty three patients were enrolled between November 2019 and October 2022. The primary endpoint was met: 6-month PFS rate was 58.8% (90% confidence interval [CI], 45.7%-72.0%). Median PFS and OS were 7.3 months (95% CI, 5.5-11.0 months) and 18.8 months (95% CI, 12.9-26.6 months), respectively. The overall response rate was 20.9% (95% CI, 10.0-36.0%) and disease control rate was 88.4% (95% CI, 74.9-96.1%). The main grade ≥3 adverse events included hypertension (62.8%), neutropenia (55.8%), leukopenia (25.6%), febrile neutropenia (11.6%), fatigue (9.3%), anorexia (9.3%), proteinuria (9.3%), and diarrhea (7.0%). No deaths and no new safety signals with a causal relation to the study treatment were observed. This study suggests that AFL plus FOLFIRI shows a high response rate and a manageable safety profile in Japanese patients with mCRC who failed prior oxaliplatin-based chemotherapy plus an anti-EGFR agent. - CA125 Kinetics as a Potential Biomarker for Peritoneal Metastasis Progression following Taxane-Plus-Ramucirumab Administration in Patients with Advanced Gastric Cancer
Akira Ueda; Satoshi Yuki; Takayuki Ando; Ayumu Hosokawa; Naokatsu Nakada; Yosuke Kito; Iori Motoo; Ken Ito; Miho Sakumura; Yurika Nakayama; Yuko Ueda; Shinya Kajiura; Koji Nakashima; Kazuaki Harada; Yasuyuki Kawamoto; Yoshito Komatsu; Ichiro Yasuda
Cancers, 16, 5, 2024年03月, [査読有り]
研究論文(学術雑誌) - 胸部食道がん化学放射線療法における重症放射線食道炎に関する後方視的研究
原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 結城 敏志; 坂本 直哉; 川本 泰之; 小松 嘉人; 打浪 雄介; 田口 大志; 加藤 徳雄; 青山 英史
北海道医学雑誌, 98, 2, 139, 140, 北海道医学会, 2023年11月
日本語 - The Short- and Long-Term Surgical Results of Consecutive Hepatopancreaticoduodenectomy for Wide-Spread Biliary Malignancy
Yasunori Yoshimi; Takehiro Noji; Keisuke Okamura; Kimitaka Tanaka; Aya Matsui; Yoshitsugu Nakanishi; Toshimichi Asano; Toru Nakamura; Takahiro Tsuchikawa; Yasuyuki Kawamoto; Kazuaki Harada; Kanako Fuyama; Kazuhumi Okada; Satoshi Hirano
Annals of Surgical Oncology, 31, 1, 90, 96, Springer Science and Business Media LLC, 2023年10月29日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Cancer-free resection (R0) is one of the most important factors for the long-term survival of biliary carcinoma. For some patients with widespread invasive cancer located between the hilar and intrapancreatic bile duct, hepatopancreaticoduodenectomy (HPD) is considered a radical surgery for R0 resection. However, HPD is associated with high morbidity and mortality rates. Furthermore, previous reports have not shown lymph node metastasis (LNM) status, such as the location or number, which could influence the prognosis after HPD. In this study, first, we explored the prognostic factors for survival, and second, we evaluated whether the LNM status (number and location of LNM) would influence the decision on surgical indications in patients with widely spread biliary malignancy. METHODS: We retrospectively reviewed the medical records of 54 patients who underwent HPD with hepatectomy in ≥2 liver sectors from January 2003 to December 2021 (HPD-G). We also evaluated 54 unresectable perihilar cholangiocarcinoma patients who underwent chemotherapy from January 2010 to December 2021 (CTx-G). RESULTS: R0 resection was performed in 48 patients (89%). The median survival time (MST) and 5-year overall survival rate of the HPD-G and CTx-G groups were 36.9 months and 31.1%, and 19.6 months and 0%, respectively. Univariate and multivariate analyses showed that pathological portal vein involvement was an independent prognostic factor for survival (MST: 18.9 months). Additionally, patients with peripancreatic LNM had worse prognoses (MST: 13.3 months) than CTx-G. CONCLUSIONS: Patients with peripancreatic LNM or PV invasion might be advised to be excluded from surgery-first indications for HPD. - Correlation of UGT1A1 Gene Polymorphisms or Prior Irinotecan Treatment and Treatment Outcomes of Nanoliposomal-Irinotecan plus 5-Fluorouracil/Leucovorin for Pancreatic Ductal Adenocarcinoma: A Multicenter, Retrospective Cohort Study (HGCSG2101).
Kazuaki Harada; Takahiro Yamamura; Osamu Muto; Michio Nakamura; Susumu Sogabe; Kentaro Sawada; Shintaro Nakano; Masataka Yagisawa; Tetsuhito Muranaka; Masayoshi Dazai; Miki Tateyama; Yoshimitsu Kobayashi; Sosuke Kato; Kazuteru Hatanaka; Yasuyuki Kawamoto; Satoshi Yuki; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
Journal of clinical medicine, 12, 4, 2023年02月17日, [査読有り], [筆頭著者, 責任著者], [国際誌]
英語, 研究論文(学術雑誌), The effects of UGT1A1 gene polymorphisms or prior irinotecan treatment on treatment outcomes of nanoliposomal-irinotecan plus 5-fluorouracil/leucovorin (nal-IRI+5-FU/LV) in patients with unresectable pancreatic ductal adenocarcinoma (PDAC) are not established. This multicenter, retrospective cohort study compared treatment outcomes in patients with UGT1A1*1/*1 and those with UGT1A1*1/*6 or *1/*28 genotypes. We also analyzed the impact of prior irinotecan treatment on survival outcomes in 54 patients treated with nal-IRI+5-FU/LV. Comparable effectiveness was found regardless of the UGT1A1 genotypes. While no significant differences were found, grade ≥3 neutropenia and febrile neutropenia were more frequent in patients with UGT1A1*1/*6 or *1/*28 than in those with UGT1A1*1/*1 genotypes (grade ≥3 neutropenia, 50.0% vs. 30.8%, p = 0.24; febrile neutropenia, 9.1% vs. 0.0%, p = 0.20, respectively). No significant difference in progression-free survival (PFS) and overall survival (OS) was observed between irinotecan-naïve-patients and other patients. However, irinotecan-resistant patients showed significantly shorter PFS (hazard ratio (HR) 2.83, p = 0.017) and OS (HR 2.58, p = 0.033) than other patients. Our study indicated that patients with UGT1A1*1/*6 or *1/*28 may be prone to neutropenia, though further study is needed. The survival benefit of nal-IRI+5-FU/LV could be maintained in patients without disease progression after irinotecan therapy. - Anti-epidermal growth factor receptor treatment for patients with NeoRAS wild-type metastatic colorectal cancer: a case report of two cases.
Kazuaki Harada; Satoshi Yuki; Yasuyuki Kawamoto; Takeaki Nakamura; Shiho Kaneko; Koichi Ishida; Naoya Sakamoto; Yoshito Komatsu
Therapeutic advances in medical oncology, 15, 17588359231216090, 17588359231216090, 2023年, [査読有り], [筆頭著者], [国際誌]
英語, The NeoRAS phenomenon is defined as the conversion of tumor RAS status from mutant-type (MT) to wild-type (WT) after systemic chemotherapy in metastatic colorectal cancer (mCRC). Cetuximab, an anti-epidermal growth factor receptor (EGFR) antibody, is effective in patients with RAS WT mCRC but ineffective in those with RAS MT mCRC; however, its outcome in patients with NeoRAS WT mCRC is unclear. Herein, we report two cases of NeoRAS WT mCRC that responded clinically to anti-EGFR treatment. The first was a 40-year-old man with synchronous peritoneal metastatic rectosigmoid cancer. The first RAS testing on tumor tissue revealed a KRAS G12C mutation, which was converted to RAS WT after two lines of chemotherapy, as assessed by liquid biopsy. After initiating irinotecan plus cetuximab treatment, a computed tomography (CT) scan revealed that malignant ascites had resolved. The treatment was discontinued after 4 months because of disease progression. The second was a 68-year-old male patient with synchronous liver metastasis from sigmoid colon cancer. The KRAS G12D mutation, initially detected in tumor tissue, was not detected by liquid biopsy after six lines of chemotherapy. Cetuximab monotherapy was initiated, and the liver metastases shrank significantly. The patient continued cetuximab monotherapy for 8 months without disease progression. Our cases demonstrate the efficacy of anti-EGFR therapy for NeoRAS WT mCRC and highlight the importance of capturing the gene mutation profile throughout the clinical course for optimal treatment selection. - 内科・外科による消化器病共同診療の現況と展望 局所進行直腸癌における術前FOLFOX療法の有効性の検討(RNAC01試験)の解釈とその発展
藤好 直; 本間 重紀; 市川 伸樹; 結城 敏志; 川本 泰之; 原田 一顕; 吉田 雅; 柴田 賢吾; 松井 博紀; 小松 嘉人; 坂本 直哉; 武冨 紹信
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 26, 26, 日本消化器病学会-北海道支部, 2022年09月
日本語 - 内科・外科による消化器病共同診療の現況と展望 当科における切除可能境界膵癌に対する術前治療の現状
原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 川本 泰之; 結城 敏志; 桑谷 将城; 田口 大志; 加藤 徳雄; 浅野 賢道; 中村 透; 平野 聡; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 131回・125回, 28, 28, 日本消化器病学会-北海道支部, 2022年09月
日本語 - Usefulness of ultrasonography and elastography in diagnosing oxaliplatin-induced sinusoidal obstruction syndrome.
Rika Saito; Yasuyuki Kawamoto; Mutsumi Nishida; Takahito Iwai; Yasuka Kikuchi; Isao Yokota; Ryo Takagi; Takahiro Yamamura; Ken Ito; Kazuaki Harada; Satoshi Yuki; Yoshito Komatsu; Naoya Sakamoto
International journal of clinical oncology, 27, 11, 1780, 1790, 2022年08月30日, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: Sinusoidal obstruction syndrome (SOS) refers to liver injury caused by hematopoietic stem cell transplantation (HSCT) and anticancer drugs including oxaliplatin. Increased splenic volume (SV) on computed tomography (CT) indicates oxaliplatin-induced SOS. Similarly, ultrasonography and liver stiffness measurement (LSM) by shear-wave elastography (SWE) can help diagnose SOS after HSCT; however, their usefulness for diagnosing oxaliplatin-induced SOS remains unclear. We investigated the usefulness of the Hokkaido ultrasonography-based scoring system with 10 ultrasonographic parameters (HokUS-10) and SWE in diagnosing oxaliplatin-induced SOS early. METHODS: In this prospective observational study, ultrasonography and SWE were performed before and at 2, 4, and 6 months after oxaliplatin-based chemotherapy. HokUS-10 was used for assessment. CT volumetry of the SV was performed in clinical practice, and an SV increase ≥ 30% was considered the diagnostic indicator of oxaliplatin-induced SOS. We assessed whether HokUS-10 and SWE can lead to an early detection of oxaliplatin-induced SOS before an increased SV on CT. RESULTS: Of the 30 enrolled patients with gastrointestinal cancers, 12 (40.0%) with an SV increase ≥ 30% on CT were diagnosed with SOS. The HokUS-10 score was not correlated with an SV increase ≥ 30% (r = 0.18). The change in rate of three HokUS-10 parameters were correlated with an SV increase ≥ 30% (r = 0.32-0.41). The change in rate of LSM by SWE was correlated with an SV increase ≥ 30% (r = 0.40). CONCLUSIONS: The usefulness of HokUS-10 score was not demonstrated; however, some HokUS-10 parameters and SWE could be useful for the early diagnosis of oxaliplatin-induced SOS. - Phase II Study of Ramucirumab Plus Irinotecan Combination Therapy as Second-Line Treatment in Patients with Advanced Gastric Cancer: HGCSG1603.
Yasuyuki Kawamoto; Satoshi Yuki; Kentaro Sawada; Michio Nakamura; Osamu Muto; Susumu Sogabe; Yoshiaki Shindo; Atsushi Ishiguro; Atsushi Sato; Yasushi Tsuji; Masayoshi Dazai; Hiroyuki Okuda; Takashi Meguro; Kazuaki Harada; Mari Sekiguchi; Kazufumi Okada; Yoichi M Ito; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
The oncologist, 27, 8, e642-e649, 2022年08月05日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Ramucirumab is a human IgG1 monoclonal vascular endothelial growth factor receptor-2 antibody that inhibits tumor cell growth and affects the tumor cell microenvironment. We assessed the efficacy and safety of ramucirumab plus irinotecan combination therapy as second-line treatment in patients with previously treated advanced gastric cancer. MATERIALS AND METHODS: Patients with advanced gastric cancer refractory or intolerant to primary chemotherapy were included. Ramucirumab 8 mg/kg plus irinotecan 150 mg/m2 combination therapy was administered every 2 weeks. The primary endpoint was progression-free survival rate at 6 months and secondary endpoints were overall survival, progression-free survival, response rate, safety, and dose intensity for each drug. RESULTS: Thirty-five patients were enrolled between January 2018 and September 2019. The progression-free survival rate at 6 months was 26.5% [95%CI, 13.2%-41.8%, P = .1353)]. Median progression-free and overall survivals were 4.2 months (95%CI, 2.5-5.4 months) and 9.6 months (95%CI, 6.4-16.6 months), respectively. The overall response rate was 25.9% (95%CI, 11.1-36.3%) and disease control rate was 85.2% (95%CI, 66.3-95.8%). Grade ≥3 adverse events that occurred in >10% of patients included neutropenia, leucopenia, anemia, anorexia, and febrile neutropenia. No death or new safety signals with a causal relation to the study treatment were observed. CONCLUSION: Although the primary endpoint was not achieved statistically, combination therapy of ramucirumab plus irinotecan showed anticancer activity and a manageable safety profile for second-line treatment of patients with advanced gastric cancer. - Analysis of the Pancreatic Cancer Microbiome Using Endoscopic Ultrasound–Guided Fine-Needle Aspiration–Derived Samples
Shintaro Nakano; Yasuyuki Kawamoto; Yoshito Komatsu; Rika Saito; Ken Ito; Takahiro Yamamura; Kazuaki Harada; Satoshi Yuki; Kazumichi Kawakubo; Ryo Sugiura; Shin Kato; Koji Hirata; Hajime Hirata; Masahito Nakajima; Ryutaro Furukawa; Yunosuke Takishin; Kousuke Nagai; Isao Yokota; Keisuke H. Ota; Shinji Nakaoka; Masaki Kuwatani; Naoya Sakamoto
Pancreas, Publish Ahead of Print, 4, 351, 357, Ovid Technologies (Wolters Kluwer Health), 2022年06月13日, [査読有り]
研究論文(学術雑誌) - Multicenter, prospective, observational study of chemotherapy-induced dysgeusia in gastrointestinal cancer.
Ken Ito; Satoshi Yuki; Hiroshi Nakatsumi; Yasuyuki Kawamoto; Kazuaki Harada; Shintaro Nakano; Rika Saito; Takayuki Ando; Kentaro Sawada; Masataka Yagisawa; Atsushi Ishiguro; Masayoshi Dazai; Ichiro Iwanaga; Kazuteru Hatanaka; Atsushi Sato; Ryusuke Matsumoto; Yoshiaki Shindo; Miki Tateyama; Tetsuhito Muranaka; Masaki Katagiri; Isao Yokota; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer, 30, 6, 5351, 5359, 2022年06月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), PURPOSE: Dysgeusia is an adverse event caused by chemotherapy. Although retrospective studies have shown zinc administration improves dysgeusia, there have been no prospective studies. The present study examined effects of zinc therapy on dysgeusia in patients with gastrointestinal cancer. METHODS: This multicenter, prospective, observational study enrolled patients with dysgeusia during chemotherapy treatment. Patients received no intervention (control), polaprezinc p.o., or zinc acetate hydrate p.o., and serum zinc levels were measured at 0 (baseline), 6, and 12 weeks. Dysgeusia was assessed using CTCAE v5.0 and subjective total taste acuity (STTA) criteria using questionnaires at baseline and 12 weeks. RESULTS: From February 2020 to June 2021, 180 patients were enrolled from 17 institutes. There were no differences in mean baseline serum zinc levels among the groups (67.3, 66.6, and 67.5 μg/dL in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. P = 0.846). The changes in mean serum zinc levels after 12 weeks were - 3.8, + 14.3, and + 46.6 μg/dL, and the efficacy rates of dysgeusia were 33.3%, 36.8%, and 34.6% using CTCAE and 33.3%, 52.6%, 32.7% using STTA in the no intervention, polaprezinc, and zinc acetate hydrate groups, respectively. The STTA scores improved in all groups, with significant improvement observed in the polaprezinc group compared with the no intervention group (P = 0.045). CONCLUSION: There was no significant correlation between the degree of serum zinc elevation and improvement in dysgeusia, suggesting that polaprezinc, but not zinc acetate hydrate, was effective in improving chemotherapy-induced dysgeusia. TRIAL REGISTRATION: UMIN000039653. Date of registration: March 2, 2020. - Study protocol of the HGCSG1803: a phase II multicentre, non-randomised, single-arm, prospective trial of combination chemotherapy with oxaliplatin, irinotecan and S-1 (OX-IRIS) as first-line treatment for metastatic or relapsed pancreatic cancer.
Shintaro Nakano; Yasuyuki Kawamoto; Satoshi Yuki; Kazuaki Harada; Takuto Miyagishima; Susumu Sogabe; Masayoshi Dazai; Atsushi Sato; Atsushi Ishiguro; Michio Nakamura; Shinya Kajiura; Yasuo Takahashi; Miki Tateyama; Kazuteru Hatanaka; Yasushi Tsuji; Takahide Sasaki; Yoshiaki Shindo; Tomoe Kobayashi; Isao Yokota; Naoya Sakamoto; Yuh Sakata; Yoshito Komatsu
BMJ open, 12, 5, e048833, 2022年05月09日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), INTRODUCTION: Combination chemotherapy with oxaliplatin, irinotecan, fluorouracil and leucovorin (FOLFIRINOX) has become one of the standard treatments for metastatic pancreatic cancer. However, the use of FOLFIRINOX requires prolonged infusion. Therefore, we planned to develop a new combination chemotherapy regimen with oxaliplatin, irinotecan and S-1 (OX-IRIS) for advanced pancreatic cancer. In the phase Ⅰ study that was conducted previously, the safety and recommended dose of OX-IRIS were assessed. In this study, we will evaluate the efficacy and safety of OX-IRIS. METHODS AND ANALYSIS: The HGCSG1803 study started as a multicentre, non-randomised, single-arm, prospective, phase II study in December 2019. Eligible subjects were patients with untreated metastatic or relapsed pancreatic cancer. OX-IRIS is administered as follows: 30 min infusion of antiemetic; 2-hour infusion of oxaliplatin (65 mg/m2); 1.5-hour infusion of irinotecan (100 mg/m2) on day 1 and 15 of each 4-week cycle; and oral S-1 (40 mg/m2) twice daily from after dinner on day one to after breakfast on day 15, followed by a 14-day rest, to be repeated every 2 weeks until disease progression, unacceptable toxicity or patient refusal. The primary endpoint is response rate. The secondary endpoints are overall and progression-free survival, safety and dose for each drug. Using a binomial test, a sample size of 40 patients was set with a threshold value of 10% and expected value of 30%. Registration of 40 cases is planned from 18 institutions in Japan. ETHICS AND DISSEMINATION: All the procedures will be conducted in accordance with the ethical standards of the responsible committee on human experimentation (institutional and national) and with the Declaration of Helsinki of 1964 and its later versions. All the patients will receive written information about the trial and will provide informed consent before enrolment. This trial was approved by the Hokkaido University Certified Review Board (approval No: 018-037). TRIAL REGISTRATION NUMBER: jRCTs011190008. - Phase II Study of Continued Trastuzumab Plus Irinotecan in Patients with HER2-positive Gastric Cancer Previously Treated with Trastuzumab (HGCSG 1201).
Yasuyuki Kawamoto; Satoshi Yuki; Takashi Meguro; Kazuteru Hatanaka; Minoru Uebayashi; Michio Nakamura; Hiroyuki Okuda; Ichiro Iwanaga; Takashi Kato; Shintaro Nakano; Atsushi Sato; Kazuaki Harada; Koji Oba; Yuh Sakata; Naoya Sakamoto; Yoshito Komatsu
The oncologist, 27, 5, 340-e374, 2022年05月06日, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The efficacy of irinotecan plus continuous trastuzumab beyond progression in patients with gastric cancer previously treated with trastuzumab plus standard first-line chemotherapy has not been reported. METHODS: Patients with human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer who were previously treated with trastuzumab received trastuzumab every 3 weeks and irinotecan every 2 weeks. The primary endpoint was the overall response rate (ORR), and the secondary endpoints included progression-free survival (PFS), 6-month survival rates, safety, and subgroup analysis by HER2 status. RESULTS: Sixteen patients were enrolled in a 3-year pre-planned registration period. This study was prematurely closed due to poor patient accrual. The ORR and disease control rate were 6.7% (95% CI, 0.2-32.0) and 53.3% (95% CI, 26.6-78.7). The median PFS and overall survival (OS) were 2.4 months (95% CI, 0.0-5.2) and 9.7 months (95% CI, 8.2-11.2), respectively. The most frequently reported grades 3-4 adverse events were neutropenia (40%), anemia (27%), anorexia (33%), and fatigue (33%). CONCLUSION: With only 16 patients enrolled, the present study has very low power to detect any clinical benefit of trastuzumab plus irinotecan beyond disease progression in patients with HER2-positive advanced gastric cancer who previously received trastuzumab.Trial Identifier: UMIN000007636. - 個別化医療を見据えた消化器診療の現状 超音波内視鏡下穿刺吸引法で得られた検体を用いた膵腫瘍内細菌叢の検討
中野 真太郎; 川本 泰之; 小松 嘉人; 伊藤 憲; 原田 一顕; 結城 敏志; 川久保 和道; 杉浦 諒; 加藤 新; 平田 幸司; 平田 甫; 中島 正人; 古川 龍太郎; 滝新 悠之介; 永井 孝輔; 横田 勲; 太田 圭祐; 中岡 慎治; 桑谷 将城; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130回・124回, 36, 36, 日本消化器病学会-北海道支部, 2022年03月
日本語 - Study protocol for HGCSG1801: A multicenter, prospective, phase II trial of second-line FOLFIRI plus aflibercept in patients with metastatic colorectal cancer refractory to anti-EGFR antibodies.
Hiroshi Nakatsumi; Yoshito Komatsu; Tetsuhito Muranaka; Satoshi Yuki; Yasuyuki Kawamoto; Kazuaki Harada; Masayoshi Dazai; Miki Tateyama; Yusuke Sasaki; Takuto Miyagishima; Yasushi Tsuji; Masaki Katagiri; Michio Nakamura; Susumu Sogabe; Kazuteru Hatanaka; Takashi Meguro; Tomoe Kobayashi; Atsushi Ishiguro; Osamu Muto; Yoshiaki Shindo; Masahito Kotaka; Takayuki Ando; Ryo Takagi; Naoya Sakamoto; Yu Sakata
Frontiers in oncology, 12, 939425, 939425, 2022年, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: The first-line chemotherapy for patients with RAS and BRAF wild-type metastatic colorectal cancer (mCRC) commonly involves cytotoxic regimens, such as FOLFOX and FOLFIRI, combined with epidermal growth factor receptor (EGFR) antibodies. When progression occurs following anti-EGFR antibody-combined chemotherapy, anti-angiogenic inhibitors can be used as second-line treatment. Although randomized controlled trials have shown that anti-angiogenic inhibitors [bevacizumab, ramucirumab, and aflibercept (AFL)] carry survival benefit when combined with FOLFIRI as second-line chemotherapy, such trials did not provide data on patients with mCRC refractory to anti-EGFR antibody-combined chemotherapy. Therefore, our group planned a multicenter, nonrandomized, single-arm, prospective, phase II study to investigate the safety and efficacy of FOLFIRI plus AFL as a second-line chemotherapy for patients with mCRC refractory to oxaliplatin-based chemotherapy combined with anti-EGFR antibodies. METHODS: FOLFIRI (irinotecan 180 mg/m2, l-leucovorin 200 mg/m2, bolus 5-FU 400 mg/m2, and infusional 5-FU 2400 mg/m2/46 h) and AFL (4 mg/kg) will be administered every 2 weeks until progression or unacceptable toxicities occur. The primary endpoint will be the 6-month progression-free survival (PFS) rate, whereas the secondary endpoints will include overall survival, PFS, response rate, disease control rate, adverse events, and relative dose intensity for each drug. A sample size of 41 participants will be required. This study will be sponsored by the Non-Profit Organization Hokkaido Gastrointestinal Cancer Study Group and will be supported by a grant from Sanofi. DISCUSSION: There is only an observational study reporting data on FOLFIRI plus AFL for patients with mCRC who previously received anti-EGFR antibodies; therefore, a prospective clinical trial is needed. This study will prospectively evaluate the efficacy and safety of FOLFIRI plus AFL in patients with mCRC who are resistant to anti-EGFR antibodies and have limited data. Moreover, this study will reveal predictive biomarkers for AFL-based chemotherapy. CLINICAL TRIAL REGISTRATION: Japan Registry of Clinical Trials, jRCTs011190006. Registered 19 November, 2019, https://jrct.niph.go.jp/latest-detail/jRCTs011190006. - A Phase I Trial of Oxaliplatin, Irinotecan, and S-1 Combination Therapy (OX-IRIS) as Chemotherapy for Unresectable Pancreatic Cancer (HGCSG 1403).
Yasuyuki Kawamoto; Hiroshi Nakatsumi; Kazuaki Harada; Tetsuhito Muranaka; Atsushi Ishiguro; Yoshimitsu Kobayashi; Hideyuki Hayashi; Satoshi Yuki; Kentaro Sawada; Masataka Yagisawa; Shintaro Nakano; Naoya Sakamoto; Yoshito Komatsu
The oncologist, 26, 10, e1675-e1682, 2021年10月, [査読有り], [国際誌]
英語, 研究論文(学術雑誌), LESSONS LEARNED: Because S-1 is orally administered, OX-IRIS does not necessitate the continuous infusion of 5-FU and is more convenient. The recommended dose of OX-IRIS was determined to be level -1 (oxaliplatin, 65 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), which has manageable safety and promising anticancer activities. BACKGROUND: OX-IRIS is a new combination therapy of oxaliplatin, irinotecan, and S-1 for unresectable pancreatic ductal adenocarcinoma (PDAC), which may be beneficial because S-1 is administered orally and continuous infusion of 5-fluorouracil (5-FU) is not needed. METHODS: Patients who had not received prior therapy for unresectable PDAC were enrolled. Adenocarcinoma or adenosquamous histology was required. Oxaliplatin and irinotecan were administered on days 1 and 15; S-1 was administered orally twice a day on days 1-14, followed by 14 days of rest (one cycle). Primary endpoints were dose-limiting toxicity (DLT) and maximum tolerated dose (MTD). Secondary endpoints were safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS). RESULTS: In level 0 (oxaliplatin, 85 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), two of five patients experienced DLT. In level -1 (oxaliplatin, 65 mg/m2 ; irinotecan, 100 mg/m2 ; S-1, 80 mg/m2 ), DLT could not be evaluated in two of eight patients because one cycle was not completed; one of the remaining six patients experienced DLT. Anemia, thrombocytopenia, fatigue, nausea, anorexia, diarrhea, and peripheral sensory neuropathy were seen frequently in levels 0 and -1. ORR was 30% in levels 0 and -1. Median progression-free survival and median overall survival were 4.1 months (95% confidence interval [CI], 0.0-8.9 months) and 13.7 months (95% CI, 4.8-22.6 months), respectively. CONCLUSION: MTD of OX-IRIS therapy was estimated to be level 0, and the recommended dose (RD) for future trial was level -1. - Impact of tumor growth rate during preceding treatment on tumor response to nivolumab or irinotecan in advanced gastric cancer
K. Kato; T. Masuishi; K. Fushiki; S. Nakano; Y. Kawamoto; Y. Narita; T. Tsushima; K. Harada; S. Kadowaki; A. Todaka; S. Yuki; M. Tajika; N. Machida; Y. Komatsu; H. Yasui; K. Muro; T. Kawakami
ESMO Open, 6, 4, Elsevier B.V., 2021年08月01日, [査読有り]
英語, 研究論文(学術雑誌) - Successful closure of huge perforation during rectal endoscopic submucosal dissection using an endoscopic string clip suturing method and polyglycolic acid sheets and fibrin glue.
Satoshi Abiko; Itsuki Sano; Ayumu Yoshikawa; Kazuaki Harada; Naoki Kawagishi; Hisashi Oda; Takuto Miyagishima
Endoscopy, 2021年07月02日, [国際誌]
英語, 研究論文(学術雑誌) - Modified search, coagulation, and clipping with polyglycolic acid sheet and fibrin glue to reduce delayed bleeding risk after endoscopic submucosal dissection near the dentate line.
Satoshi Abiko; Ayumu Yoshikawa; Kazuaki Harada; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
Endoscopy, 2021年04月16日, [国際誌]
英語, 研究論文(学術雑誌) - Feasibility of a modified search, coagulation, and clipping method with and without the use of polyglycolic acid sheets and fibrin glue for preventing delayed bleeding after gastric endoscopic submucosal dissection.
Satoshi Abiko; Soichiro Oda; Akimitsu Meno; Akane Shido; Sonoe Yoshida; Ayumu Yoshikawa; Kazuaki Harada; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
BMC gastroenterology, 21, 1, 63, 63, 2021年02月11日, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: Methods have been developed for preventing delayed bleeding (DB) after gastric endoscopic submucosal dissection (GESD). However, none of the methods can completely prevent DB. We hypothesized that DB could be prevented by a modified search, coagulation, and clipping (MSCC) method for patients at low risk for DB and by combining the use of polyglycolic acid sheets and fibrin glue with the MSCC method (PMSCC method) for patients at high risk for DB (antibleeding [ABI] strategy). This study assessed the technical feasibility of this novel strategy. METHOD: We investigated 123 lesions in 121 consecutive patients who underwent GESD in Kushiro Rosai Hospital between April 2018 and January 2020. The decision for continuation or cessation of antithrombotic agents was based on the Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment. RESULTS: Oral antithrombotic agents were administered to 28 patients (22.8%). The en bloc R0 resection rate was 98.4%. The MSCC method and the PMSCC method for preventing DB were performed in 114 and 9 lesions, respectively. The median time of the MSCC method was 16 min, and the median speed (the resection area divided by the time of method used) was 3.6 cm2/10 min. The median time of the PMSCC method was 59 min, and the median speed was 1.3 cm2/10 min. The only delayed procedural adverse event was DB in 1 (0.8%) of the 123 lesions. CONCLUSIONS: The ABI strategy is feasible for preventing DB both in patients at low risk and in those at high risk for DB after GESD, whereas the PMSCC method may be necessary for reduction of time. - A Pitfall of Endoscopic String Clip Suturing.
Satoshi Abiko; Soichiro Oda; Akimitsu Meno; Akane Shido; Sonoe Yoshida; Ayumu Yoshikawa; Kazuaki Harada; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
ACG case reports journal, 7, 11, e00470, 2020年11月, [国際誌]
英語, 研究論文(学術雑誌) - Impact of single-heterozygous UGT1A1 on the clinical outcomes of irinotecan monotherapy after fluoropyrimidine and platinum-based combination therapy for gastric cancer: a multicenter retrospective study.
Shintaro Nakano; Satoshi Yuki; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Takayuki Ando; Shinya Kajiura; Ayumu Yoshikawa; Kazuaki Harada; Kazuteru Hatanaka; Aya Tanimoto; Atsushi Ishiguro; Takuya Honda; Masayoshi Dazai; Takahide Sasaki; Naoya Sakamoto; Yoshito Komatsu
International journal of clinical oncology, 25, 10, 1800, 1806, 2020年10月, [査読有り], [国内誌]
英語, 研究論文(学術雑誌), BACKGROUND: It is unclear whether the UGT1A1 status, single heterozygous (SH) or wild type (WT), is associated with the efficacy and toxicity of irinotecan monotherapy in advanced gastric cancer (AGC). We investigated the association between clinical outcomes (efficacy and safety) and UGT1A1 status in patients who received irinotecan monotherapy. METHODS: We evaluated AGC patients who received irinotecan monotherapy between January 2011 and December 2017. Efficacy was assessed according to overall survival (OS) and progression-free survival (PFS). Toxicity was graded using the Common Toxicity Criteria for Adverse Events (version 4.0). RESULTS: A total of 100 patients were evaluated (62 and 38 patients with UGT1A1 WT and SH, respectively). In the WT and SH groups, the irinotecan dose was reduced in 19 (30.6%) and 18 (47.2%) patients (p = 0.135), respectively; treatment was delayed due to adverse events (AEs) in 19 (30.6%) and 13 (34.2%) patients (p = 0.826), respectively; the median PFS was 3.15 and 3.25 months (HR, 0.734; 95% CI 0.465-1.158; p = 0.184), respectively; and the median OS was 10.4 and 7.26 months (HR, 1.137; 95% CI 0.752-1.721; p = 0.543), respectively. Severe hematological AEs (Grade ≥ 3) were significantly more frequent in the SH group than in the WT group (63% vs. 36%; p = 0.008), while severe non-hematological AEs was not significantly different (16.0% vs. 6.5%; p = 0.173). CONCLUSION: There was no significant difference in the efficacy of irinotecan monotherapy between UGT1A1 WT and UGT1A1 SH, but UGT1A1 SH was associated with a high frequency of severe hematological toxicity. - Combination of search, coagulation, clipping, and polyglycolic acid sheet to prevent delayed bleeding after gastric endoscopic submucosal dissection.
Satoshi Abiko; Ayumu Yoshikawa; Kazuaki Harada; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
Endoscopy, 52, 9, E344-E345, 2020年09月, [国際誌]
英語, 研究論文(学術雑誌) - Feasibility of a new ligation using the double-loop clips technique without an adhesive agent for ulceration after endoscopic submucosal dissection of the colon (with video).
Satoshi Abiko; Sonoe Yoshida; Ayumu Yoshikawa; Kazuaki Harada; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
Gastrointestinal endoscopy, 92, 2, 415, 421, 2020年08月, [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND AND AIMS: Several ligation techniques for ulceration after endoscopic submucosal dissection (ESD) have been reported, but none have been established for clinical use because of technical complexity and the need for expensive equipment. Therefore, the technical feasibility of a new ligation method using the double-loop clips (D-L clips) technique without an adhesive agent for ulceration after ESD of the colon was assessed. METHODS: Among 35 patients who underwent ESD of the colon in Kushiro Rosai Hospital between April 2019 and September 2019, 26 patients who underwent ligation using the D-L clips technique for the post-ESD ulcer bed were included in this retrospective study. Continuation or cessation of antithrombotic agents was based on the Guidelines for Gastroenterological Endoscopy in Patients Undergoing Antithrombotic Treatment. RESULTS: The rate of en bloc R0 resection was 97.1%, the median length of the resected specimen was 3.2 cm (interquartile range [IQR], 2.8-3.8 cm), and the complete ligation rate was 88.5% (23 of 26). Excluding patients with lesion sites in the rectum below the peritoneal reflection, the complete ligation rate was 95.5% (21 of 22). The median duration of the ligation procedure was 20 minutes (IQR, 16-24 minutes). The only delayed procedural adverse event was post-ESD coagulation syndrome in 1 patient. Incomplete ligation was significantly more frequent in patients with lesion sites in the inferior rectal valve/anal verge area (P = .0269). CONCLUSIONS: Ligation using the D-L clips technique without an adhesive agent is feasible for closing ulceration after ESD of the colon, whereas other techniques may be necessary for lesions in the rectum below the peritoneal reflection. - Pericardial tamponade during pembrolizumab treatment in a patient with advanced lung adenocarcinoma: A case report and review of the literature.
Kazuaki Harada; Makoto Ogasawara; Akane Shido; Akimitsu Meno; Soichiro Oda; Shota Yoshida; Sonoe Yoshida; Ayumu Yoshikawa; Ko Ebata; Satoshi Abiko; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
Thoracic cancer, 11, 5, 1350, 1353, 2020年05月, [査読有り], [筆頭著者, 責任著者], [国際誌]
英語, 研究論文(学術雑誌), Several studies have demonstrated increased pericardial effusion during anti-PD-1 immunotherapy, and treatment in patients who have developed pericardial tamponade is controversial. In this study, we describe a 63-year-old woman with stage IVA lung adenocarcinoma given pembrolizumab as a first-line therapy. After four cycles of pembrolizumab treatment, the patient suddenly developed a pericardial tamponade. Although pericardial effusion was increased, her tumor lesions were reduced. After an emergency pericardiocentesis, she continued the pembrolizumab therapy without recurrent pericardial effusions for three months until the primary tumor and lymph node metastasis progressed. Nine months after the pericardiocentesis, the patient died of progressive lung cancer, but pericardial effusion did not recur throughout the treatment course. This case study suggests that pembrolizumab therapy can be continued with a strict follow-up in some patients with pembrolizumab-induced pericardial tamponade. KEY POINTS: • Significant findings of the study Our patient developed pericardial tamponade during pembrolizumab treatment but continued pembrolizumab treatment after emergency pericardiocentesis without recurrent pericardial effusions. • What this study adds Pembrolizumab treatments may be resumed with a strict follow-up in some patients with treatment-related pericardial tamponade. - Usefulness of a clutch cutter combined with an S-O clip in improving stability when opening the pocket in the pocket-creation method.
Satoshi Abiko; Ayumu Yoshikawa; Kazuaki Harada; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
Endoscopy, 52, 4, E128-E129, 2020年04月, [国際誌]
英語, 研究論文(学術雑誌) - New ligation technique using a double loop clip without adhesive for ulceration following endoscopic submucosal dissection of the colon.
Satoshi Abiko; Ayumu Yoshikawa; Kazuaki Harada; Naoki Kawagishi; Itsuki Sano; Hisashi Oda; Takuto Miyagishima
Endoscopy, 52, 1, E20-E21, 2020年01月, [国際誌]
英語, 研究論文(学術雑誌) - Comparative sequence analysis of patient-matched primary colorectal cancer, metastatic, and recurrent metastatic tumors after adjuvant FOLFOX chemotherapy.
Kazuaki Harada; Wataru Okamoto; Sachiyo Mimaki; Yasuyuki Kawamoto; Hideaki Bando; Riu Yamashita; Satoshi Yuki; Takayuki Yoshino; Yoshito Komatsu; Atsushi Ohtsu; Naoya Sakamoto; Katsuya Tsuchihara
BMC cancer, 19, 1, 255, 255, 2019年03月21日, [査読有り], [筆頭著者], [国際誌]
英語, 研究論文(学術雑誌), BACKGROUND: In the era of genome-guided personalized cancer treatment, we must understand chemotherapy-induced genomic changes in tumors. This study evaluated whether adjuvant FOLFOX chemotherapy modifies the mutational profile of recurrent colorectal cancer (CRC). METHODS: Whole exome sequencing was performed on samples from primary CRC tumors, untreated metastatic tumors, and recurrent tumors following adjuvant FOLFOX chemotherapy. The samples were resected from four patients. RESULTS: The number of mutations or the mutation spectrum in individual patients was nearly identical. Copy number variants persisted regardless of FOLFOX therapy administration. The genomic signature of oxaliplatin exposure (G > T/C > A, T > A/A > T) was not enriched after FOLFOX chemotherapy. Overlapping single nucleotide variants (SNVs) and indels remained in 26-65% of the patient-matched tumor samples. One patient harbored an AKT1 E17K mutation in the recurrent tumor, whereas PIK3CA E542K and E88Q mutations were detected in the primary and untreated metastatic tumor samples. Genes related to intracellular Ca2+ homeostasis were enriched among the genes uniquely mutated after FOLFOX chemotherapy. CONCLUSIONS: We found that the mutation rates, mutation spectrum, and copy number variants were nearly identical regardless of the administration of FOLFOX therapy in the four CRC cases. The mutational discordance between the patient-matched tumor samples is likely caused by tumor heterogeneity and chemotherapy-induced clonal selection. These findings might be useful as pilot data for larger studies to clarify the changes in the mutational landscape induced by adjuvant FOLFOX chemotherapy. - Study protocol of HGCSG1404 SNOW study: a phase I/II trial of combined chemotherapy of S-1, nab-paclitaxel and oxaliplatin administered biweekly to patients with advanced gastric cancer
Yasuyuki Kawamoto; Yoshito Komatsu; Satoshi Yuki; Kentaro Sawada; Tetsuhito Muranaka; Kazuaki Harada; Hiroshi Nakatsumi; Hiraku Fukushima; Atsushi Ishiguro; Masayoshi Dazai; Kazuteru Hatanaka; Michio Nakamura; Ichiro Iwanaga; Minoru Uebayashi; Susumu Sogabe; Yoshimitsu Kobayashi; Takuto Miyagishima; Kota Ono; Naoya Sakamoto; Yuh Sakata
BMC CANCER, 17, 1, 837, 2017年12月, [査読有り]
英語, 研究論文(学術雑誌) - HGCSG 1201: Phase II study of trastuzumab with irinotecan in HER2-positive metastatic or advanced gastric cancer patients previously treated with trastuzumab
Sasaki Takahide; Kawamoto Yasuyuki; Yuki Satoshi; Meguro Takashi; Hatanaka Kazuteru; Uebayashi Minoru; Iwanaga Ichiro; Nakamura Michio; Eto Kazunori; Okuda Hiroyuki; Abe Masakazu; Oba Ayane; Abe Nobuhiko; Sato Atsushi; Nakatsumi Hiroshi; Harada Kazuaki; Muranaka Tetsuhito; Yagisawa Masataka; Oba Koji; Sakata Yuh; Komatsu Yoshito
ANNALS OF ONCOLOGY, 28, 2017年06月, [査読有り]
英語 - Efficacy and Safety of Bolus 5-Fluorouracil and L-Leucovorin as Salvage Chemotherapy for Oral Fluoropyrimidine-Resistant Unresectable or Recurrent Gastric Cancer: A Single Center Experience
Tetsuhito Muranaka; Satoshi Yuki; Yoshito Komatsu; Kentaro Sawada; Kazuaki Harada; Yasuyuki Kawamoto; Hiroshi Nakatsumi; Naoya Sakamoto
JOURNAL OF GASTRIC CANCER, 16, 3, 177, 181, 2016年09月, [査読有り]
英語, 研究論文(学術雑誌) - Successful treatment of advanced sigmoid colon cancer with liver metastases with cetuximab monotherapy as first-line treatment - A case report
Kazuaki Harada; Kazuteru Hatanaka; Kenji Kinoshita; Yasuyuki Kawamoto; Hiroaki Yamato; Koji Ogawa; Yoshiya Yamamoto; Hirohito Naruse
Japanese Journal of Cancer and Chemotherapy, 41, 7, 897, 900, Japanese Journal of Cancer and Chemotherapy Publishers Inc., 2014年07月01日, [筆頭著者]
日本語, 研究論文(学術雑誌) - [New molecular targeting drugs for metastatic colorectal cancer].
Komatsu Y; Harada K; Fukushima H; Yuki S
Nihon rinsho. Japanese journal of clinical medicine, 72, 1, 120, 126, 1, 2014年01月, [国内誌]
日本語, 研究論文(学術雑誌), I explain an outline of the molecular target of new drugs for colorectal cancer. First, regorafenib is an orally active, multikinase inhibitor. Second, as angiogenesis inhibitors, aflibercept and ramucirumab. Aflibercept is the second anti-angiogenic agent after bevacizumab with a FDA approval for metastatic colorectal cancer. Ramucirumab is a fully human mAb that binds human VEGFR-2, thus blocking VEGF binding and inhibiting angiogenesis. Finally, I introduce a new combination chemotherapy regimen with molecular targetting drugs. - 【最新胃癌学-基礎と臨床の最新研究動向-】 胃癌の治療戦略 化学療法 胃癌への化学療法 概論
小松 嘉人; 結城 敏志; 福島 拓; 佐々木 尚英; 小林 良充; 原田 一顕
日本臨床, 72, 増刊1 最新胃癌学, 431, 437, (株)日本臨床社, 2014年01月
日本語 - 【大腸癌の最新治療-治癒に向けた最先端研究-】 臨床研究 治療 分子標的薬治療 新規薬剤 大腸癌の新しい分子標的治療
小松 嘉人; 原田 一顕; 福島 拓; 結城 敏志
日本臨床, 72, 1, 120, 126, (株)日本臨床社, 2014年01月
日本語
- 高齢者における消化管癌の薬物療法の現状 進行再発結腸直腸癌に対するIRIS/Bevの多施設共同後方視的観察研究(HGCSG1901) 高齢者の治療成績
原田 一顕; 伊藤 憲; 結城 敏志; 川本 泰之; 吉河 歩; 澤田 憲太郎; 石黒 敦; 武藤 理; 畑中 一映; 奥田 博介; 佐藤 温; 笹木 有佑; 中村 路夫; 目黒 高志; 植田 亮; 坂本 直哉; 坂田 優; 小松 嘉人, 日本消化管学会雑誌, 9, Suppl., 204, 204, 2025年01月
(一社)日本消化管学会, 日本語 - HER2陽性大腸癌の臨床的特徴に関する多施設共同後ろ向き研究(HGCSG2304)
金子志帆; 澤田憲太郎; 畑中一映; 太宰昌佳; 中積宏之; 安藤孝将; 小高雅人; 辻靖; 中村路夫; 武藤理; 目黒高志; 横山達也; 石田浩一; 中村赳晶; 原田一顕; 川本泰之; 結城敏志; 坂本直哉; 坂田優; 小松嘉人, 日本臨床腫瘍学会学術集会(CD-ROM), 22nd, 2025年 - 当院における切除不能胆道癌に対するゲムシタビン+シスプラチン+デュルバルマブ療法の使用経験
横山 達也; 川本 泰之; 原田 一顕; 中村 赳晶; 石田 浩一; 金子 志帆; 結城 敏志; 小松 嘉人; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 135回・129回, 47, 47, 2024年08月
日本消化器病学会-北海道支部, 日本語 - 消化器癌患者における鉄欠乏性貧血に対するカルボキシマルトース第二鉄の有用性の検討
川本 泰之; 原田 一顕; 金子 志帆; 石田 浩一; 中村 赳晶; 結城 敏志; 小松 嘉人; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 134回・128回, 75, 75, 2024年03月
日本消化器病学会-北海道支部, 日本語 - 切除不能進行再発大腸癌の治療戦略 転移性結腸直腸癌におけるレゴラフェニブ減量開始の有用性を検討する多施設共同後方視的解析
結城 敏志; 原田 一顕; 小松 嘉人; 坂本 直哉; 川上 武志; 山崎 健太郎; 舛石 俊樹; 谷口 浩也; 胡 慶江; 沖 英次, 日本消化器病学会雑誌, 121, 臨増総会, A73, A73, 2024年03月
(一財)日本消化器病学会, 日本語 - 当科におけるがん悪液質患者へのアナモレリン塩酸塩の使用経験
石田 浩一; 川本 泰之; 金子 志帆; 中村 赳晶; 原田 一顕; 結城 敏志; 小松 嘉人; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 133回・127回, 59, 59, 2023年09月
日本消化器病学会-北海道支部, 日本語 - 実臨床における切除不能進行・再発胆道癌に対するGEM+CDDP+S-1療法(GCS)と三剤逐次投与のの治療成績に関する検討
川本 泰之; 原田 一顕; 坂本 直哉; 中村 赳晶; 金子 志帆; 石田 浩一; 結城 敏志; 桑谷 将城; 小松 嘉人, 胆道, 37, 3, 597, 597, 2023年08月
(一社)日本胆道学会, 日本語 - HGCSG1901 転移性大腸癌に対するIRIS/Bevの後方視的検討 UGT1A1 single heterozygousが与える影響
結城 敏志; 伊藤 憲; 原田 一顕; 川本 泰之; 八木澤 允貴; 澤田 憲太郎; 石黒 敦; 武藤 理; 畑中 一映; 奥田 博介; 佐藤 温; 笹木 有佑; 中村 路夫; 目黒 高志; 太宰 昌佳; 中積 宏之; 植田 亮; 坂本 直哉; 坂田 優; 小松 嘉人, 日本消化器病学会雑誌, 120, 臨増総会, A295, A295, 2023年03月
(一財)日本消化器病学会, 日本語 - S-1による術後補助化学療法中に早期再発しペムブロリズマブが著効したMSI-high胃癌の1例
渡辺 亮介; 原田 一顕; 中村 赳晶; 山村 貴洋; 川本 泰之; 結城 敏志; 小松 嘉人; 坂本 直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 132回・126回, 60, 60, 2023年03月
日本消化器病学会-北海道支部, 日本語 - 進行胆嚢癌に対する肝・膵切除術の妥当性
野路 武寛; 武内 慎太郎; 和田 雅孝; 田中 公貴; 松井 あや; 中西 喜嗣; 浅野 賢道; 中村 透; 土川 貴裕; 原田 一顕; 川本 泰之; 平野 聡, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 132回・126回, 67, 67, 2023年03月
日本消化器病学会-北海道支部, 日本語 - 腸内細菌叢に影響を与える薬剤の投与歴と胃癌化学療法の治療効果に関する検討
中村 赳晶; 渡辺 亮介; 山村 貴洋; 原田 一顕; 川本 泰之; 結城 敏志; 小松 嘉人; 坂本 直哉, 日本胃癌学会総会記事, 95回, 415, 415, 2023年02月
(一社)日本胃癌学会, 日本語 - 高齢者・非高齢者の転移を有する膵癌患者の臨床的背景と薬物療法治療成績に関する単施設後方視的検討
川本泰之; 川本泰之; 原田一顕; 山村貴洋; 山村貴洋; 渡辺亮介; 中村赳晶; 中村赳晶; 結城敏志; 桑谷将城; 桑谷将城; 小松嘉人; 坂本直哉, 日本高齢消化器病学会誌, 25, 2, 2023年 - 実臨床における切除不能進行・再発胆道癌に対するGEM+CDDP+S-1療法(GCS)と三剤逐次投与の治療成績に関する検討
川本泰之; 川本泰之; 原田一顕; 坂本直哉; 中村赳晶; 金子志帆; 石田浩一; 結城敏志; 桑谷将城; 小松嘉人, 胆道(Web), 37, 3, 2023年 - 切除不能進行・再発胆道がんに対するがん遺伝子関連検査と個別化医療の現状
川本泰之; 川本泰之; 原田一顕; 山村貴洋; 山村貴洋; 斎藤里佳; 斎藤里佳; 伊藤憲; 伊藤憲; 結城敏志; 桑谷将城; 小松嘉人; 小松嘉人; 坂本直哉, 日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 130th-124th, 2022年 - 高齢者・非高齢者に転移を有する膵癌患者の臨床的背景と薬物療法治療成績に関する単施設後方視的検討
川本泰之; 川本泰之; 渡辺亮介; 中村赳晶; 中村赳晶; 山村貴洋; 山村貴洋; 原田一顕; 結城敏志; 桑谷将城; 小松嘉人; 坂本直哉, 日本高齢消化器病学会誌, 25, 1, 2022年 - 転移を有する高齢・非高齢膵がん患者の臨床的背景と薬物療法治療成績の後方視的検討
川本泰之; 川本泰之; 渡辺亮介; 中村赳晶; 中村赳晶; 山村貴洋; 山村貴洋; 原田一顕; 結城敏志; 桑谷将城; 桑谷将城; 小松嘉人; 坂本直哉, 日本癌治療学会学術集会(Web), 60th, 2022年 - チューターのいない施設の大腸ESDにおけるpocket-creation method+paper cutting techniqueの実現可能性試験
安孫子怜史; 安孫子怜史; 甲谷理紗子; 東野真幸; 鈴木和治; 杉浦諒; 宮本秀一; 木下賢治; 畑中一映; 山本義也; 小田総一郎; 目野晃光; 志藤茜; 吉田苑永; 吉河歩; 原田一顕; 川岸直樹; 佐野逸紀; 小田寿; 成瀬宏仁; 宮城島拓人, Gastroenterological Endoscopy (Web), 63, Supplement2, 2021年 - 切除不能進行・再発胆道癌に対するGEM・CDDP・S-1の逐次投与と同時併用投与の比較検討
川本泰之; 小松嘉人; 山村貴洋; 斎藤里佳; 伊藤憲; 原田一顕; 結城敏志; 桑谷将城; 坂本直哉, 日本癌治療学会学術集会(Web), 59th, 2021年 - Oxaliplatinによる類洞閉塞症候群の診断における腹部超音波検査の有用性の検討
斎藤 里佳; 西田 睦; 岩井 孝仁; 菊池 穏香; 吉野 裕紀; 横田 勲; 高木 諒; 川本 泰之; 山村 貴洋; 伊藤 憲; 中野 真太郎; 原田 一顕; 結城 敏志; 小松 嘉人; 坂本 直哉, 日本癌治療学会学術集会抄録集, 58回, P, 178, 2020年10月
(一社)日本癌治療学会, 英語 - 食道癌の治療中に横紋筋融解症を発症したことを契機に診断された甲状腺機能低下症の一例
大江悠希; 亀田啓; 関崎知紀; 宮愛香; 野本博司; 曹圭龍; 中村昭伸; 原田一顕; 結城敏志; 小松嘉人; 坂本直哉; 三好秀明; 三好秀明; 渥美達也, 日本内分泌学会雑誌, 96, 4 (Web), 976, 976, 2020年
(一社)日本内分泌学会, 日本語 - Budd-Chiari症候群に対しPercutaneous transluminal angioplastyが奏功した一例
吉田 苑永; 川岸 直樹; 小田 総一郎; 志藤 茜; 目野 晃光; 吉河 歩; 安孫子 怜史; 原田 一顕; 佐野 逸紀; 小田 寿; 須田 剛生; 小川 浩司; 吉野 裕紀; 阿保 大介; 宮城島 拓人; 坂本 直哉, 日本消化器病学会北海道支部例会プログラム・抄録集, 125回, 31, 31, 2019年09月
日本消化器病学会-北海道支部, 日本語 - 同種末梢血幹細胞移植8年後に発症した若年発症の食道扁平上皮癌の1例
村中 徹人; 小松 嘉人; 原田 一顕; 中積 宏之; 川本 泰之; 結城 敏志; 山本 桂子; 清水 勇一; 坂本 直哉; 海老原 裕磨; 倉島 庸; 七戸 俊明; 三橋 智子, 北海道医学雑誌, 92, 2, 111, 112, 2017年11月
北海道医学会, 日本語 - Phase II trial of Panitumumab for patients with KRAS exon2 wild type mCRC after progression on Cetuximab: HGCSG1101
Ayumu Hosokawa; Satoshi Yuki; Kazuaki Harada; Yasushi Tsuji; Kazuteru Hatanaka; Atsushi Sato; Yoshimitsu Kobayashi; Hiroyuki Okuda; Yuh Sakata; Yoshito Komatsu, ANNALS OF ONCOLOGY, 28, 2017年10月
英語, 研究発表ペーパー・要旨(国際会議) - A retrospective cohort study evaluating the safety and efficacy of regorafenib in patients with metastatic colorectal cancer [HGCSG1401]: Analysis of tumor location
Yuki Satoshi; Komatsu Yoshito; Muranaka Tetsuhito; Tsuji Yasushi; Harada Kazuaki; Ota Yumiko; Hatanaka Kazuteru; Okuda Hiroyuki; Sasaki Takahide; Dazai Masayoshi; Konno Jun; Nakamura Michio; Ohta Tomoyuki; Honda Takuya; Ishiguro Atsushi; Muto Osamu; Kato Sosuke; Sato Atsushi; Abe Masakazu; Eto Kazunori; Sakamoto Naoya; Sakata Yuh, ANNALS OF ONCOLOGY, 28, 2017年06月
英語, 研究発表ペーパー・要旨(国際会議) - A retrospective cohort study of the relations between progress of chemotherapy and outcomes for metastatic pancreatic cancer
Kawamoto Yasuyuki; Yuki Satoshi; Yagisawa Masataka; Muranaka Tetsuhito; Harada Kazuaki; Nakatsumi Hiroshi; Kawakubo Kazumichi; Kuwatani Masaki; Sakamoto Naoya; Komatsu Yoshito, ANNALS OF ONCOLOGY, 28, 2017年06月
英語, 研究発表ペーパー・要旨(国際会議) - イマチニブ耐性GISTに対するスニチニブの有効性・安全性(Retrospective analysis of the efficacy and safety of sunitinib in patients with advanced GIST)
中積 宏之; 小松 嘉人; 村中 徹人; 原田 一顕; 川本 泰之; 結城 敏志; 坂本 直哉, 日本胃癌学会総会記事, 89回, 259, 259, 2017年03月
(一社)日本胃癌学会, 英語 - 進行胃癌化学療法時の成分栄養剤併用の有効性に関する探索的臨床試験 HGCSG1202(Feasibility study to evaluate the efficacy of elemental diet with chemotherapy for AGC: HGCSG1202)
結城 敏志; 小松 嘉人; 中積 宏之; 川本 泰之; 原田 一顕; 村中 徹人; 畑中 一映; 曽我部 進; 中村 路夫; 武藤 理; 奥田 博介; 佐藤 温; 江藤 和範; 坂本 直哉; 坂田 優, 日本胃癌学会総会記事, 89回, 345, 345, 2017年03月
(一社)日本胃癌学会, 英語 - 食道 食道がんの再発治療・二次治療 食道癌の二次化学療法におけるDocetaxelおよびPaclitaxelの有効性・安全性の検討
中積 宏之; 小松 嘉人; 村中 徹人; 原田 一顕; 川本 泰之; 結城 敏志; 坂本 直哉, 日本癌治療学会学術集会抄録集, 54回, WS72, 6, 2016年10月
(一社)日本癌治療学会, 日本語 - 切除不能転移性病変を有するステージIV大腸癌における原発巣切除の意義
市川 伸樹; 本間 重紀; 吉田 雅; 大野 陽介; 渋谷 一陽; 川村 秀樹; 川本 泰之; 村中 徹人; 原田 一顕; 中積 宏之; 結城 敏志; 小松 嘉人; 武冨 紹信, 日本大腸肛門病学会雑誌, 69, 抄録号, A279, A279, 2016年10月
(一社)日本大腸肛門病学会, 日本語 - Observational cohort study of first-line bevacizumab combined with chemotherapy in metastatic colorectal cancer (HGCSG0802): Sub-group analysis by KRAS Exon2 status
Takenori Takahata; Satoshi Yuki; Hiroshi Nakatsumi; Kazuaki Harada; Hiraku Fukushima; Atsushi Sato; Takashi Kato; Takashi Meguro; Michio Nakamura; Nobuyuki Ehira; Ichiro Iwanaga; Miki Tateyama; Kazuteru Hatanaka; Kazunori Eto; Hiroyuki Okuda; Yoshimitsu Kobayashi; Osamu Muto; Masakazu Abe; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 33, 3, 2015年01月
英語, 研究発表ペーパー・要旨(国際会議) - OBSERVATIONAL COHORT STUDY OF 1ST LINE BEVACIZUMAB COMBINED WITH CHEMOTHERAPY IN METASTATIC COLORECTAL CANCER: HGCSG0802
Michio Nakamura; Satoshi Yuki; Kazuaki Harada; Yoshimitsu Kobayashi; Takashi Kato; Minoru Uebayashi; Norikazu Sonoda; Kazunori Eto; Takenori Takahata; Yoshito Komatsu, ANNALS OF ONCOLOGY, 25, 2014年10月
英語, 研究発表ペーパー・要旨(国際会議) - ANALYSIS OF GLASGOW PROGNOSTIC SCORE(GPS) IN KRAS EXON2 WILD TYPE PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC) TREATED WITH SALVAGE-LINE CETUXIMAB-BASED REGIMEN: HGCSG0901
Yuki Satoshi; Komatsu Yoshito; Harada Kazuaki; Fukushima Hiraku; Sasaki Takahide; Kobayashi Yoshimitsu; Tsuji Yasushi; Naruse Hirohito; Okuda Hiroyuki; Takahashi Yasuo; Hosokawa Ayumu; Konno Jun; Eto Kazunori; Kudo Mineo; Kawamoto Yasuyuki; Sonoda Norikazu; Sato Yasushi; Uebayashi Minoru; Kato Takashi; Onodera Manabu; Ohta Tomoyuki; Sakata Yuh, ANNALS OF ONCOLOGY, 25, 2014年06月
英語, 研究発表ペーパー・要旨(国際会議) - Exploratory randomized trial to evaluate the effect of indisetron tablets for preventing chemotherapy-induced nausea and vomiting (CINV)/acute-onset diarrhea induced by IRIS/FOLFIRI: HGCSG0704.
Sosuke Kato; Hiraku Fukushima; Kanji Kato; Satoshi Yuki; Kazuaki Harada; Yoshimitsu Kobayashi; Takahide Sasaki; Nobuyuki Ehira; Ichiro Iwanaga; Minoru Uebayashi; Masayoshi Dazai; Susumu Sogabe; Takuto Miyagishima; Mineo Kudo; Kazuteru Hatanaka; Hirohito Naruse; Miki Tateyama; Yuh Sakata; Yoshito Komatsu, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Phase II trial of S-1 plus split cisplatin (SSP) in patients with advanced gastric cancer (HGCSG0702): Final report.
Satoshi Yuki; Yoshito Komatsu; Hiraku Fukushima; Takahide Sasaki; Yoshimitsu Kobayashi; Kazuaki Harada; Masayoshi Dazai; Susumu Sogabe; Takuto Miyagishima; Atsushi Ishiguro; Takenori Takahata; Atsushi Sato; Mineo Kudo; Sosuke Kato; Kanji Kato; Ichiro Iwanaga; Nobuyuki Ehira; Minoru Uebayashi; Yuh Sakata, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - The efficacy of first-line IRIS with or without bevacizumab in patients with metastatic colorectal cancer: Including multivariate analysis of two phase II studies
Satoshi Yuki; Yoshito Komatsu; Hiraku Fukushima; Takahide Sasaki; Yoshimitsu Kobayashi; Kazuaki Harada; Toraji Amano; Michio Nakamura; Mineo Kudo; Miki Tateyama; Kazuteru Hatanaka; Soh Saitoh; Takuto Miyagishima; Takashi Kato; Yasuyuki Kawamoto; Tomofumi Takagi; Ichiro Iwanaga; Kencho Miyashita; Manabu Onodera; Yuh Sakata, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - Evaluation of usefulness of Royal Marsden Hospital prognostic index in second-line chemotherapy of advanced gastric cancer.
Takahide Sasaki; Yoshito Komatsu; Satoshi Yuki; Kazuaki Harada; Yoshimitsu Kobayashi; Hiraku Fukushima; Naoya Sakamoto, JOURNAL OF CLINICAL ONCOLOGY, 32, 3, 2014年01月
英語, 研究発表ペーパー・要旨(国際会議) - 当院における臨床病期II/III食道癌に対する治療の検討
畑中 一映; 川本 泰之; 木下 賢治; 原田 一顕; 大和 弘明; 小川 浩司; 山本 義也; 成瀬 宏仁; 遠山 茂; 喜多村 圭; 工藤 和洋, 函館医学誌, 37, 1, 7, 10, 2013年10月
当院では、切除可能な臨床病期II/III食道癌に対して2003年から術前化学放射線療法を施行しているが、近年は根治的化学放射線療法を希望選択する患者も増えている。今回、2005〜2012年に本症の治療を行った56例を治療法別に、術前化学放射線療法後手術群32例(NeoCRT+S群)、手術先行群9例(S群)、根治的化学放射線療法群15例(根治的CRT群)に分け、治療成績を比較検討した。2年生存率は、NeoCRT+S群が64%、S群が78%、根治的CRT群が42%であった。根治的CRT群の治療効果は、CRが2例、PRが5例、NCが6例、PDが2例であり、奏効率46.6%、腫瘍制御率86.7%であった。NeoCRT+S群の無増悪生存率は、1年で79%、2年で70%であった。, 市立函館病院, 日本語 - ダブルバルーン小腸内視鏡で診断された十二指腸水平部癌の1例
原田 一顕; 藤澤 倫子; 大野 正芳; 大和 弘明; 小川 浩司; 畑中 一映; 山本 義也; 成瀬 宏仁; 遠山 茂; 倉内 宣明; 原 豊; 笠島 浩行; 田原 宗徳; 加藤 雅志; 山名 大輔; 江本 慎; 木村 純; 工藤 和洋; 下山 則彦, 道南医学会大会並びに総会プログラム・抄録集, 64回, 22, 22, 2011年11月
道南医学会, 日本語
- 高齢者における消化管癌の薬物療法の現状 進行再発結腸直腸癌に対するIRIS/Bevの多施設共同後方視的観察研究(HGCSG1901) 高齢者の治療成績
原田 一顕; 伊藤 憲; 結城 敏志; 川本 泰之; 吉河 歩; 澤田 憲太郎; 石黒 敦; 武藤 理; 畑中 一映; 奥田 博介; 佐藤 温; 笹木 有佑; 中村 路夫; 目黒 高志; 植田 亮; 坂本 直哉; 坂田 優; 小松 嘉人
日本消化管学会雑誌, 2025年01月, (一社)日本消化管学会, 日本語
2025年01月 - 2025年01月 - 消化器癌に対するS-1を含む全身化学療法による眼障害に関する前向き観察研究
八木澤 允貴; 中村 路夫; 澤田 憲太郎; 川本 泰之; 村中 徹人; 中積 宏之; 太宰 昌佳; 辻 靖; 進藤 吉明; 中野 真太郎; 上林 実; 渡邉 桃子; 原田 一顕; 結城 敏志; 小松 嘉人
日本癌治療学会学術集会抄録集, 2024年10月, (一社)日本癌治療学会, 英語
2024年10月 - 2024年10月 - がん悪液質に対するアナモレリン塩酸塩の早期中止と関連する因子の検討(HGCSG2201)
原田 一顕; 梶浦 新也; 澤田 憲太郎; 畑中 一映; 佐藤 温; 伊藤 憲; 田村 穂高; 土井 綾子; 安藤 孝将; 中村 路夫; 中積 宏之; 村中 徹人; 小松 嘉人
日本癌治療学会学術集会抄録集, 2024年10月, (一社)日本癌治療学会, 英語
2024年10月 - 2024年10月 - 当院における切除不能胆道癌に対するゲムシタビン+シスプラチン+デュルバルマブ療法の使用経験
横山 達也; 川本 泰之; 原田 一顕; 中村 赳晶; 石田 浩一; 金子 志帆; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2024年08月, 日本消化器病学会-北海道支部, 日本語
2024年08月 - 2024年08月 - 消化器癌患者における鉄欠乏性貧血に対するカルボキシマルトース第二鉄の有用性の検討
川本 泰之; 原田 一顕; 金子 志帆; 石田 浩一; 中村 赳晶; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2024年03月, 日本消化器病学会-北海道支部, 日本語
2024年03月 - 2024年03月 - 切除不能進行再発大腸癌の治療戦略 転移性結腸直腸癌におけるレゴラフェニブ減量開始の有用性を検討する多施設共同後方視的解析
結城 敏志; 原田 一顕; 小松 嘉人; 坂本 直哉; 川上 武志; 山崎 健太郎; 舛石 俊樹; 谷口 浩也; 胡 慶江; 沖 英次
日本消化器病学会雑誌, 2024年03月, (一財)日本消化器病学会, 日本語
2024年03月 - 2024年03月 - 局所進行胃癌に対してNivolumab併用術前化学療法を施行し治癒切除が得られた1例
田路 悠太; 武内 慎太郎; 林 真理子; 岡村 国茂; 三浦 巧; 倉島 庸; 海老原 裕磨; 村上 壮一; 七戸 俊明; 平野 聡; 頼永 聡子; 原田 一顕; 外丸 詩野
北海道外科雑誌, 2023年12月, 北海道外科学会, 日本語
2023年12月 - 2023年12月 - 胸部食道がん化学放射線療法における重症放射線食道炎に関する後方視的研究
原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 結城 敏志; 坂本 直哉; 川本 泰之; 小松 嘉人; 打浪 雄介; 田口 大志; 加藤 徳雄; 青山 英史
北海道医学雑誌, 2023年11月, 北海道医学会, 日本語
2023年11月 - 2023年11月 - 転移性大腸癌におけるレゴラフェニブの開始用量が治療成績に対する影響
胡 慶江; 原田 一顕; 川上 武志; 緒方 貴次; 伏木 邦博; 谷口 浩也; 室 圭; 安藤 幸滋; 南原 翔; 川本 泰之; 小松 嘉人; 沖 英次; 舛石 俊樹; 山崎 健太郎; 結城 敏志
日本癌治療学会学術集会抄録集, 2023年10月, (一社)日本癌治療学会, 英語
2023年10月 - 2023年10月 - 当科におけるがん悪液質患者へのアナモレリン塩酸塩の使用経験
石田 浩一; 川本 泰之; 金子 志帆; 中村 赳晶; 原田 一顕; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2023年09月, 日本消化器病学会-北海道支部, 日本語
2023年09月 - 2023年09月 - 実臨床における切除不能進行・再発胆道癌に対するGEM+CDDP+S-1療法(GCS)と三剤逐次投与のの治療成績に関する検討
川本 泰之; 原田 一顕; 坂本 直哉; 中村 赳晶; 金子 志帆; 石田 浩一; 結城 敏志; 桑谷 将城; 小松 嘉人
胆道, 2023年08月, (一社)日本胆道学会, 日本語
2023年08月 - 2023年08月 - HGCSG1901 転移性大腸癌に対するIRIS/Bevの後方視的検討 UGT1A1 single heterozygousが与える影響
結城 敏志; 伊藤 憲; 原田 一顕; 川本 泰之; 八木澤 允貴; 澤田 憲太郎; 石黒 敦; 武藤 理; 畑中 一映; 奥田 博介; 佐藤 温; 笹木 有佑; 中村 路夫; 目黒 高志; 太宰 昌佳; 中積 宏之; 植田 亮; 坂本 直哉; 坂田 優; 小松 嘉人
日本消化器病学会雑誌, 2023年03月, (一財)日本消化器病学会, 日本語
2023年03月 - 2023年03月 - S-1による術後補助化学療法中に早期再発しペムブロリズマブが著効したMSI-high胃癌の1例
渡辺 亮介; 原田 一顕; 中村 赳晶; 山村 貴洋; 川本 泰之; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2023年03月, 日本消化器病学会-北海道支部, 日本語
2023年03月 - 2023年03月 - 進行胆嚢癌に対する肝・膵切除術の妥当性
野路 武寛; 武内 慎太郎; 和田 雅孝; 田中 公貴; 松井 あや; 中西 喜嗣; 浅野 賢道; 中村 透; 土川 貴裕; 原田 一顕; 川本 泰之; 平野 聡
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2023年03月, 日本消化器病学会-北海道支部, 日本語
2023年03月 - 2023年03月 - 腸内細菌叢に影響を与える薬剤の投与歴と胃癌化学療法の治療効果に関する検討
中村 赳晶; 渡辺 亮介; 山村 貴洋; 原田 一顕; 川本 泰之; 結城 敏志; 小松 嘉人; 坂本 直哉
日本胃癌学会総会記事, 2023年02月, (一社)日本胃癌学会, 日本語
2023年02月 - 2023年02月 - 内科・外科による消化器病共同診療の現況と展望 局所進行直腸癌における術前FOLFOX療法の有効性の検討(RNAC01試験)の解釈とその発展
藤好 直; 本間 重紀; 市川 伸樹; 結城 敏志; 川本 泰之; 原田 一顕; 吉田 雅; 柴田 賢吾; 松井 博紀; 小松 嘉人; 坂本 直哉; 武冨 紹信
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年09月, 日本消化器病学会-北海道支部, 日本語
2022年09月 - 2022年09月 - 内科・外科による消化器病共同診療の現況と展望 当科における切除可能境界膵癌に対する術前治療の現状
原田 一顕; 中村 赳晶; 渡辺 亮介; 山村 貴洋; 川本 泰之; 結城 敏志; 桑谷 将城; 田口 大志; 加藤 徳雄; 浅野 賢道; 中村 透; 平野 聡; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年09月, 日本消化器病学会-北海道支部, 日本語
2022年09月 - 2022年09月 - 個別化医療を見据えた消化器診療の現状 超音波内視鏡下穿刺吸引法で得られた検体を用いた膵腫瘍内細菌叢の検討
中野 真太郎; 川本 泰之; 小松 嘉人; 伊藤 憲; 原田 一顕; 結城 敏志; 川久保 和道; 杉浦 諒; 加藤 新; 平田 幸司; 平田 甫; 中島 正人; 古川 龍太郎; 滝新 悠之介; 永井 孝輔; 横田 勲; 太田 圭祐; 中岡 慎治; 桑谷 将城; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2022年03月, 日本消化器病学会-北海道支部, 日本語
2022年03月 - 2022年03月 - HGCSG2101 実臨床における進行膵癌に対するnal/IRI+5-FU/LVの治療成績
山村 貴洋; 原田 一顕; 曽我部 進; 澤田 憲太郎; 八木澤 允貴; 中野 真太郎; 太宰 昌佳; 舘山 美樹; 伊藤 憲; 斎藤 里佳; 川本 泰之; 結城 敏志; 坂本 直哉; 坂田 優; 小松 嘉人
日本癌治療学会学術集会抄録集, 2021年10月, (一社)日本癌治療学会, 英語
2021年10月 - 2021年10月 - P4-10 The impact of neutrophil/lymphocyte ratio (NLR) on overall survival for patients with metastatic colorectal cancer
Kazuaki Harada; Takeshi Kawakami; Toshiki Masuishi; Yasuyuki Kawamoto; Hirohumi Go; Kyoko Kato; Ryosuke Kumanishi; Satoshi Yuki; Kouji Yamamoto; Hirofumi Yasui; Yoshito Komatsu; Kei Muro; Takeharu Yamanaka; Kentaro Yamazaki
Annals of Oncology, 2021年07月, Elsevier BV
2021年07月 - 2021年07月 - IRIS/Bev療法時の下痢に対する半夏瀉心湯予防投与の第二相試験 生存期間の解析
原田 一顕; 中積 宏之; 川本 泰之; 結城 敏志; 石黒 敦; 舘山 美樹; 宮城島 拓人; 中村 路夫; 太宰 昌佳; 奥田 博介; 畑中 一映; 天野 虎次; 小松 嘉人
日本癌治療学会学術集会抄録集, 2020年10月, (一社)日本癌治療学会, 英語
2020年10月 - 2020年10月 - 消化管間質腫瘍(GIST)におけるレゴラフェニブ治療と骨格筋量の変化に関する検討
伊藤 憲; 原田 一顕; 川本 泰之; 中積 宏之; 中野 真太郎; 斎藤 里佳; 山村 貴洋; 結城 敏志; 小松 嘉人; 坂本 直哉
日本消化器病学会北海道支部例会・日本消化器内視鏡学会北海道支部例会プログラム・抄録集, 2020年10月, 日本消化器病学会-北海道支部, 日本語
2020年10月 - 2020年10月 - S-1またはカペシタビンを含む標準治療に不応・不耐の胃癌に対するbolus 5-FU/I-LV療法の多施設共同第II相試験 前治療別の解析
村中 徹人; 小松 嘉人; 結城 敏志; 中野 真太郎; 澤田 憲太郎; 川本 泰之; 中積 宏之; 原田 一顕; 宮城島 拓人; 畑中 一映; 太宰 昌佳; 植田 亮; 笹木 祐介; 辻 靖; 西本 尚樹; 坂田 優; 坂本 直哉
日本消化管学会雑誌, 2020年01月, (一社)日本消化管学会, 日本語
2020年01月 - 2020年01月 - 自己免疫性肝炎に対して長期間アザチオプリンを使用後発症したびまん性大細胞型B細胞リンパ腫
吉田 匠汰; 江端 浩; 原田 一顕; 川岸 直樹; 谷野 美智枝; 武井 英博; 押味 和夫; 宮城島 拓人
臨床血液, 2019年11月, (一社)日本血液学会-東京事務局, 日本語
2019年11月 - 2019年11月 - 経口フッ化ピリミジン不応の胃がんに対するRPMI療法(HGCSG1502試験)OS・QOL解析結果
太宰 昌佳; 村中 徹人; 川本 泰之; 中積 宏之; 原田 一顕; 宮城島 拓人; 畑中 一映; 植田 亮; 加藤 総介; 笹木 有佑; 結城 敏志; 坂本 直哉; 西本 尚樹; 坂田 優; 小松 嘉人
日本癌治療学会学術集会抄録集, 2019年10月, (一社)日本癌治療学会, 英語
2019年10月 - 2019年10月 - Stage III結腸癌の術後補助化学療法としてのFOLFOX療法の第II相臨床試験 NORTH/HGCSG1003
岩永 一郎; 結城 敏志; 七戸 俊明; 高橋 典彦; 川本 泰之; 中積 宏之; 久須美 貴哉; 中村 文隆; 原田 一顕; 伊藤 陽一; 坂本 直哉; 平野 聡; 武冨 紹信; 小松 嘉人
日本消化器病学会北海道支部例会プログラム・抄録集, 2019年09月, 日本消化器病学会-北海道支部, 日本語
2019年09月 - 2019年09月 - 当院におけるc-Stage2/3食道癌に対する治療の検討
畑中 一映; 川本 泰之; 木下 賢二; 原田 一顕; 大和 弘明; 小川 浩司; 山本 義也; 成瀬 宏仁; 遠山 茂; 喜多村 圭; 下山 則彦; 工藤 和洋
日本消化器病学会雑誌, 2013年02月, (一財)日本消化器病学会, 日本語
2013年02月 - 2013年02月 - 超音波内視鏡下、総胆管・十二指腸内瘻術を施行した1例
成瀬 宏仁; 木下 賢治; 原田 一顕; 川本 泰之; 大和 弘明; 小川 浩司; 畑中 一映; 山本 義也; 工藤 和洋; 下山 則彦
道南医学会大会並びに総会プログラム・抄録集, 2012年11月, 道南医学会, 日本語
2012年11月 - 2012年11月 - 当院におけるc-Stage II/III食道癌に対する治療の検討
畑中 一映; 川本 泰之; 木下 賢治; 原田 一顕; 大和 弘明; 小川 浩司; 山本 義也; 成瀬 宏仁; 遠山 茂; 喜多村 圭; 下山 則彦; 工藤 和洋
道南医学会大会並びに総会プログラム・抄録集, 2012年11月, 道南医学会, 日本語
2012年11月 - 2012年11月 - 虫垂粘液嚢腫により腸重積をきたした1例
東出 侑子; 木下 賢治; 原田 一顕; 川本 泰之; 大和 弘明; 小川 浩司; 畑中 一映; 山本 義也; 成瀬 宏仁; 工藤 和洋; 下山 則彦
道南医学会大会並びに総会プログラム・抄録集, 2012年11月, 道南医学会, 日本語
2012年11月 - 2012年11月 - 粘膜下腫瘍の形態を呈した直腸粘液癌の1例
中村 晃久; 木下 賢治; 原田 一顕; 川本 泰之; 大和 弘明; 小川 浩司; 畑中 一映; 山本 義也; 成瀬 宏仁; 工藤 和洋; 下山 則彦
道南医学会大会並びに総会プログラム・抄録集, 2012年11月, 道南医学会, 日本語
2012年11月 - 2012年11月
